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SUMMARY 
The work described in this dissertation concerns the three 
antibiotics vancomycin (a potent antibiotic against Gram-positive 
bacteria), ristocetin A (a member of the vancomycin group of antibiotics), 
and triostin A (a DNA intercalating quinoxaline antibiotic). 
The precise nature of the vancomycin binding site has been mapped 
out with reference to that of the related antibiotic ristocetin A. The 
bacterial cell wall analogue Ac 2-L-lys-D-ala-D-ala was synthesised by a 
new simple method and was then used in these studies. The solution 
conformations of triostin A are described in some detail. Both of these 
studies have involved the extensive use of high-field (270 and 400MHz) 
proton nmr spectroscopy and the development of associated techniques, such 
as difference spectra and the nuclear Overhauser effect, to determine 
intra and inter-molecular interactions. 
An extensive crystallisation program has resulted in the first 
method for the reproducible crystallisation of ristocetin A. A number of 
solvents were found to produce crystals but only water/75% acetone 
produced the quality necessary for x-ray crystallography. Unfortunately 
these proved unstable upon bombardment by x-rays and the desired crystal 
structure of ristocetin A has not been obtained. Crystals were also 
obtained of ristocetin A complexed to the bacterial cell wall analogues 
Ac-D-ala-D-ala and Ac2-L-lys-D-ala-D-ala, al though crystal structures 
were not determined because of the large unit cell of the complex with the 
former and -the instability of the complex with the latter. Attempted 
crystallisations of derivatives of ristocetin A and of vancomycin were 
completely without success. 
1. INTRODUCTION 
1.1 VANCOMYCIN 
CONTENTS 
1.2 RISTOCETIN A 2 
1.3 TRIOSTIN A 3 
2. PREVIOUS STRUCTURAL STUDIES 5 
2. 1 VANCOMYCIN 5 
2.2 RISTOCETIN A 8 
2.3 TRIOSTIN A 10 
3. TIIE BACTERIAL CELL WALL 14 
3. 1 INTRODUCTION 14 
3.2 PEPTIDOGLYCAN STRUCTURE 15 
3.3 PEPTIDOGLYCAN BIOSYNTHESIS 15 
4. NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 17 
4. 1 PULSED FT NMR 17 
4.2 DOUBLE IRRADIATION TECHNIQUES 19 
4.2. 1 SPIN-DECOUPLING 20 
4.2.2 THE NUCLEAR OVERHAUSER EFFECT 20 
4.2.3 DIFFERENCE SPECTRA 21 
4.3 CHEMICAL EXCHANGE 22 
4. 3. 1 TRANSFER OF SATURATION 22 
5. PREVIOUS BINDING STUDIES ON VANCOMYCIN-TYPE ANTIBIOTICS 24 
5. 1 VANCOMYCIN 26 
5.2 RISTOCETIN A 29 
6. PRESENT STUDIES 32 
6.1 VANCOMYCIN - REFINEMENT OF STRUCTURE AND BINDING SITE 32 
6. 1. 1 SYNTHESIS OF AC 2-L-LYSYL-D-ALANYL-D-ALANINE 37 
6.1.2 VANCOMYCIN/AC-D-ALA-D-ALA BINDING STUDIES. 40 
6.1.3 VANCOMYCIN /AC 2-L-LYS-D-ALA-D-ALA BINDING STUDIES 51 
6.1.4 CRYSTALLISATION STUDIES 57 
6. 1.5 EPILOGUE 57 
6.2 RISTOCETIN A - CRYSTALLISATION STUDIES 58 
6.3 TRIOSTIN A 60 
7. CONCLUSIONS 70 
7. 1 VANCOMYCIN 70 
7.2 RISTOCETIN A 71 
7.3 TRIOSTIN A 72 
7.4 NMR SPECTROSCOPY 73 
8. EXPERIMENTAL 74 
8. 1 PREPARATIONS 75 
8. 1, 1 AC-D-ALA-D-ALA 75 
8.1.2 N-HYDROXYSUCCINIMIDE 75 
8.1.3 t-BUTYLOXYCARBONYL-D-ALANINE 76 
8. 1.4 D-ALANINE BENZYL ESTER - 1 76 
8. 1.5 D-ALANINE BENZYL ESTER p-TOLUENE SULPHONIC ACID SALT 77 
8.1.6 D-ALANINE BENZYL ESTER - 2 78 
8. 1. 7 D-ALANYL-D-ALANINE BENZYL ESTER - 1 78 
8.1.8 D-ALANYL-D-ALANINE BENZYL ESTER 
p-TOLUENE SULPHONIC ACID SALT 
8.1.9 D-ALANYL-D-ALANINE BENZYL ESTER - 2 
8. 1. 10 L-ALANINE BENZYL ESTER HYDROCHLORIDE 
8.1.11 N,N1-DI-ACETYL-L-LYSINE 
8. 1. 12 DI-t-BOC-L-LYSINE 
8.1.13 DI-t-BOC-L-LYSINE SUCCINIMIDE ESTER 
8.1. 14 N,N 1-DI-CBZ-L-LYSINE SUCCINIMIDE ESTER 
8.1.15 N,N 1-DI-CBZ-L-LYS-D-ALA BENZYL ESTER 
8.1.16 N,N 1-DI-CBZ-L-LYS-D-ALA-D-ALA BENZYL ESTER 
8.1.17 N,N 1-AC 2-L-LYS-D-ALA-D-ALA 
8. 1. 18 RISTOCETIN IODIDE SALT 
8.1.19 RISTOCETIN-\.V-AGLYCONE 
8.2 CRYSTALLISATION STUDIES 
8.2. 1 TECHNIQUES 
8.2.2 VANCOMYCIN 
8.2,3 VANCOMYCIN/AC-D-ALA-D-ALA 
8.2.4 RISTOCETIN A 
8.2. 5 RISTOCETIN-\.V-AGLYCONE 
8.2.6 RISTOCETIN A/PEPTIDE 
79 
80 
80 
80 
81 
82 
82 
83 
84 
84 
86 
86 
87 
87 
87 
88 
89 
94 
95 
8.3 NMR EXPERIMENTS 
9. REFERENCES 
APPENDIX 1 
96 
98 
103 
1. INTRODUCTION 
This dissertation describes investigations performed on the 
antibiotics vancomycin, ristocetin A and triostin A. For clarity and 
comparison certain chapters have been subdivided according to antibiotic. 
1. 1 VANCOMYCIN 
Vancomycin was the first member of a group of structurally similar 
water-soluble glycopeptide antibiotics to be isolated and therefore lends 
its name to the class as a whole. It was elucidated by McCormick and co-
workers 1 from Streptomyces orientalis and is active against Gram-positive 
bacteria. Other members of the group are ristocetin [ 1] , ristomycin2, 
avoparcin3, actinoidin 4, antibiotic A35512B5, teichomycin 6 and antibiotic 
A46967. Several of them are isolated as more than one variant, for example 
ristocetin and actinoidin in A and B forms. They are of considerable 
interest because bacteria do not readily develop resistance to them and no 
naturally resistant strain has ever been found. Vancomycin, ristocetin, 
avoparcin and A4696 are all effective in increasing food utilisation and 
for the prevention and treatment of ketosis8 (a condition characterised by 
the accumulation of ketones in blood; often found with high-fat, low-
carbohydrate diets, or in starvation). The potential market for animal 
feed additives therefore exists. Due to adverse side effects, vancomycin 
is the only member of the group in clinical use, even so it is only 
tolerable in the treatment of serious illness. It is used in the treatment 
of staphylococcal infections9 (for example wound septicaemia and 
pneumonia) when other antibiotics are ineffective and, because it is 
absorbed poorly by the gastro-intestinal tract, is normally administered 
intravenously in doses of 2g per day for 2-3 weeks . However, recently it 
[ t ] See Section 1. 2 
has been reported 10, 11 that oral administration of vancomycin (2g/d) is 
effective in the treatment of post-operative diarrhoea, a symptom of 
antibiotic-associated colitis. This intestinal infection is due to 
Clostridium difficile, an organism which multiplies and produces toxins 
when the usual gut flora have been largely eliminated by the use of broad 
spectrum antibiotics. The infection is usually eliminated within 7 days of 
the onset of treatment with vancomycin. 
The determination of the structure of vancomycin ( figure 1. 1) is 
described in section 2. 1, the final details being obtained from an x-ray 
analysis of a crystalline degradation product ( CDP-I) in which the 
asparagine residue of vancomycin was hydrolysed to aspartic acid with the 
consequent loss of ammonia. 
The nomenclature shown in figure 1. 1 is referred to throughout this 
dissertation. 
1.2 RISTOCETIN A 
The antibiotic ristocetin, a member of the vancomycin group of 
antibiotics, was first isolated by Grundy 12 from the actinomycete Nocardia 
lurida. Philip and co-workers 13 separated the antibiotic into two 
biologically active variants, termed A and B, which had identical aglycone 
structures but differed in the carbohydrate moieties. The A-form had six 
sugars whereas the B-form had only four. The structure of ristocetin 
(figure 1.2) has been determined with contributions from many groups of 
workers [2] , including studies on the antibiotic ristomycin, isolated 
from Proactinomyces fructifera 2, which was later proved to be identical in 
structure to ristocetin 14 in both variants. The apparent difference 
between them may have owed more to an ambiguity in classification 15 
between the groups of workers than to any real genetic variation of the 
actinomycete producing the antibiotic. Unlike vancomycin, the structure of 
[2] See Section 2. 2 
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ristocetin has not been confirmed by x-ray analysis because of the 
difficulty experienced in obtaining suitable crystals. 
Ristocetin B had three times the activity of the A-form 13. 
Furthermore, the mild acid hydrolysates 16 (with most or all of the sugars 
removed) of both forms showed similarly enhanced activities compared to 
the parent antibiotics. Ristocetin A, like vancomycin, causes 
precipitation of fibrinogen and other plasma proteins. An additional 
effect caused by ristocetin A but not vancomycin is the aggregation of 
blood platelets which has led to the withdrawal of ristocetin A from 
clinical use 17. However, it has found peripheral use as an important 
diagnostic tool in the identification of various bleeding disorders such 
as the Bernard Soulier syndrome 18 and von Willebrand's disease l9, 20. Recent 
evidence 21 has shown that mild acid hydrolysis of ristocetin A, to remove 
all of the sugars except for the amino sugar ristosamine, produces an 
antibiotic with enhanced activity (as previously noted), but more 
importantly with the complete removal of the platelet aggregation 
tendency. 
The nomenclature shown in figure 1.2 is referred to throughout this 
dissertation and has been made as consistent as possible with that used 
for the related antibiotic vancomycin. 
1.3 TRIOS.TIN A 
The quinoxaline antibiotics triostin A22 and echinomycin23 are 
members of a group of cross-bridged cyclic octadepsipeptides, 
characterised by the presence of quinoxaline-2-carboxylic acid moieties 
and are elucidated from several streptomycetes related to Streptomyces 
aureus (for example Streptomyces triostinius for triostin A). Recently the 
total synthesis of a naturally occurring quinoxaline antibiotic24•25 (des-
N-tetramethyl triostin A) was accomplished. The molecule, named tandem, 
only differs from triostin A in lacking the N-methylation of four peptide 
bonds, and is the only quinoxaline antibiotic for which an x-ray structure 
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has been obtained 26. The similarities in structure can readily be 
appr eciated from figure 1. 3. 
The quinoxal ine antibiotics are effective against Gram-positive 
bacteria but not against Gram-negative organisms, presumably because the y 
fail to penetrate the outer membrane of Gram-negative bacteria [3] . In 
addition they are powerfully cytotoxic to mammalian cells and have some 
limited use as expe r imental anticancer agents in man. This latter action 
has been traced to their interaction with DNA. The binding of each 
t r iostin A molecule extends the double helix by an amount consistent with 
the intercalation of both of its quinoxaline rings, at locations two base-
pai r s apart 27. To permit this insertion there must be preliminary local 
unwinding of the double helix to produce spaces between the stacked pairs 
into which the planar quinoxaline ring system can move. The hydrogen-
bonding between the base-pairs remains undisturbed although there is some 
distortion of the smooth coil of the sugar phosphate backbone as the 
intercalated molecules maintain the double helix in a partially unwound 
configuration . 
The integrity of the octapeptide ring and the cross-bridge are 
essential for intercalation with DNA. The nature of the cross-bridge is 
thought to account for the different affinities 28 of echinomycin , which 
favours poly- d(G - C), and t r iost in A, which favours poly-d( A-T ). 
[3] See Chapter 3 
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2. PREVIOUS STRUCTURAL STUDIES 
2. 1 VANCOMYCIN 
Early studies on vancomycin 29 suggested the presence of aromatic, 
aliphatic hydroxyls, phenolic hydroxyls , amino and carboxylic groups in 
addition to peptide bonds. A molecular weight of approximately 3300 
Daltons was proposed by McCormick 1 but Johnson30 later suggested that this 
value was due to dimerisation of the antibiotic in solution and the actual 
molecular weight was around 1560 Daltons. This was later confirmed3 1,32 
and in due course the molecular weight was established as 1448 Daltons, 
corresponding to a molecular formula of c66 H75 c1 2N9o24. Hydrolysis of 
vancomycin by boiling in 0.6M hydrochloric acid for 2 minutes produced a 
white precipitate termed aglucovancomycin and liberated the sugars 
glucose 29 and vancosamine33,34 (2.1 ). Large amber crystals of another 
derivative, called GDP-I, were formed when an aqueous solution (pH 4,2) of 
vancomycin was heated at 70°-ao 0 c for 1-2 days. One mole of ammonia was 
lost during the reaction due to the conversion of a primary amide group to 
a ca r boxylate3 1. Treatment of GDP-I with hydrochloric acid under the same 
conditions as those used for the preparation of aglucovancomycin gave a 
white precipitate , termed GDP-II, and in addition glucose and vancosamine 
wer e liber ated. The r elationship between vancomycin and its derivatives is 
illustrated schematically in figure 2. 1. 
Hydro~ysis of vancomycin in 6M hydrochloric acid produced L-
aspa r tic acid, N-methyl-D-leucine and vancomycin acid (3 - methyl-4 -
ketoheptanoic acid) 29. Vancomycin acid was later shown to be derived from 
the amino sugar vancosamine33, and N- methyl-D- leucine was identified as an 
N-te r mi nal amino acid30, 
Nitration of agl ucov ancomycin followed by pe rmanganate oxidat i on 
produced 3-chloro- 4- hyd r oxybenzoic acid (2 .2) and 3- chloro- 4- hydroxy- 5-
ni trobenzoic acid (2. 3) 29. However, at t empts to isolate larg er ch l or i ne-
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containing fragments were unsuccessful until the antibiotic was first 
protected by methylation of the phenols prior to oxidation3 1,35. Acidic 
products were isolated and methylated to yield the triester (2.4). The 
attachment of the sugars to the aromatic rings was determined by 
methylation of vancomycin, removal of the sugars by methanolysis, 
trideuteriomethylation, oxidation and finally methylation of the 
resulting carboxylic acid residues. Fragment (2.5) was isolated and 
established that in vancomycin a sugar was glycosidically attached to the 
central oxygen atom of ring 2 of (2.4). Related experiments showed that 
vancosamine was glycosidically attached to the C-2 of glucose, and that 
glucose was glycosidically linked to ring 2 of fragment (2.4)3 1. 
One further fragment . identified from the oxidation experiments3 1 
was dimethyl-4-methoxyisophthalate (2.6). In addition, when vancomycin was 
hydrolysed with 4M sodium hydroxide under reflux and subsequently 
methylated, fragment (2.7) was identified35. It was proposed that (2.6) was 
derived from the 1,2,4,-trisubstituted ring of (2.7) and that the original 
fragment in the antibiotic was a biphenyl (2.8), the hydroxyl group being 
replaced by nitrogen during alkaline hydrolysis. The most probable 
mechanism for the formation of (2.7) from the biphenyl unit is shown in 
scheme 2. 1. 
The components described so far account for most of the molecular 
formula of vancomycin. However, the studies of Johnson30 revealed that 
base-catalysed hydrolysis of vancomycin afforded approximately 2 moles of 
glycine, although this amino acid was not produced in significant amounts 
from acid-catalysed hydrolysis. This led to the proposal36 that glycine 
may have arisen via a base-catalysed retro-aldol cleavage of a p -hydroxy 
amino acid ((2.9) in scheme 2.2). The products would be an aldehyde (2.10) 
and, by hydrolytic cleavage of the bonds indicated by wavy lines and 
ketonisation of the product, glycine (2.11). Two units such as (2.9) would 
give rise to approximately 2 moles of glycine. Since an aldehyde would be 
unlikely to survive the conditions necessary for alkaline hydrolysis, the 
reaction was performed (on methylated aglucovancomycin) in the presence 
of sodium borohydride (or deuterioborohydride) in situ. Fragment (2.12) 
was isolated by reaction with the former; and (2.13) was obtained in the 
presence of the latter. On the basis of these experiments, it was concluded 
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that vancomycin contained the major structural component (2. 14). 
Having identified the four structural units as N-methyl-D-leucine, 
L-aspartic acid , the biphenyl uni t (2.8), and the disaccha r ide triaryl 
ether unit (2.14), the problem remained of establishing the six 
interconnecting peptide bonds in such a manner as to leave free one 
carboxylate and one primary amide group. In addition, the stereochemistry 
of seven of the nine asymmetric carbon atoms (the other two centres having 
already been identified as L-aspartic acid and N-methyl-D-leucine) was 
unsolved . Mass spectroscopic analysis36 identified that one of the 
potential glycine units in vancomycin was attached via a secondary amide 
bond to the C-terminus of N-methyl-D-leucine. Nuclear magnetic resonance 
studies at 270MHz37 established from coupling constant data that 
vancosamine and glucose were present as a - and p- anomers respectively. 
In addition, lanthanide shift experiments identified the carbonyl of ring 
A in (2.8) as being the position of the free carboxylate group of 
vancomycin. The application of the nuclear Over ha user effect ( nOe ) 37, 
which monitors the interaction of the magnetic fields of nuclei that are 
close in space [ 1 J , established the relative orientation of all the 
structural units of vancomycin. The nOe also provided evidence for the 
attachment of the carbonyl group of ring C of (2.14) to the amino group of 
aspartic acid in vancomycin37. Since the stereochemistry at seven 
asymmetric centres remained unknown it proved impossible to establish a 
total structure. The final details of the molecule (figure 2.2) were 
provided by x-ray analysis of GDP-I 38. 
[1] Full description in Section 4.2.2 
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2.2 RISTOCETIN A 
As stated previously ristocetin A and Bare believed to be identical 
to ristomycin A and B 14 respectively, thus data pertaining to the latter 
pair of antibiotics can be directly assimilated with the former pair of 
antibiotics. 
Mild acid hydrolysis of ristomycin A39 liberated D-arabinose, D-
mannose (2.15), L-rhamnose, D-glucose and an amino sugar ristosamine 
(2.16), in the ratio 1:2:1:1:1. The B-form of the antibiotic contained only 
L-rhamnose, D-mannose and D-glucose as the neutral sugars39, in the ratio 
1: 1: 1. Lomakina and co-workers 40 deduced the sequence of the sugars in 
ristomycin A and B by identifying the oligosaccharides formed in a series 
of mild acid hydrolyses. The nature and positions of the sugar linkages in 
a tetrasaccharide unit (2.17) was established by Sztaricskai and co-
workers41, although only recently has the ring size of the arabinose unit 
been confirmed 42 , 43 as that shown. The structure of ristosamine (2.16) has 
been confirmed by synthesis 44. The carbohydrate portion of ristocetin A 
was thus accounted for by (2.15), (2.16) and (2.17); each sugar component 
being attached via glycosidic bonds at three separate points of the 
agl ycone 45. 
The aglycone moiety of ristocetin ( identical in both A and B 
forms39) was initially studied by chemical degradation (acid and base 
hydrolyses, and oxidation) followed by isolation and characterisation of 
the fragments. The identified structural units were then assembled as the 
complete aglycone entity using high-field 1H and 13c nmr studies. 
Strong . acid hydrolysis (6M hydrochloric acid, 105°C, 18h) of 
ristocetin had been known for some time to produce several aromatic amino 
acids but it was not until the work of Tarbell and co-workers 46 , 47 that the 
structure of one of the components was identified as ( 2. 18). Further 
work 14, 47 identified the presence of (2.19) , which had already been shown 
to be present in vancomycin [2]. 
[2] See Section 2. 1 
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Oxidative degradation of the protected ristocetin aglycone, 
followed by methylation of the acidic products led to isolation and 
characterisation of the triaryl ether residue 47 (2.20). On the basis of 
obvious structural analogy between the fragments of ristocetin and the 
structure of vancomycin, it was reasonable to suppose that ristocetin 
contained the structural unit (2.21 ), and indeed this was confirmed using 
reductive alkaline hydrolysis experiments 48, 49, similar to those carried 
out on vancomycin. 
The molecular weight of ristocetin A was determined 14 by 
californium plasma desorption mass spectroscopy (2063 ± 5 Daltons) and in 
conjunction with 1H and 13c nmr studies 14 the structural units (2.15), 
(2.16), (2.17), (2.18), (2.19) and (2.21) were identified as constituting 
essentially all of the ristocetin A molecule. However, the problem 
remained of deducing the manner in which the components were coordinated 
and the stereochemistry of the nine asymmetric centres. Fortunately the 
structural similarities between vancomycin (as determined by x-ray 
studies) and ristocetin A, and the fact that both were able to bind to 
peptidoglycans terminating in -D-ala-D-ala, indicated that the 
similarities were likely to extend to stereochemical detail. Further 
studies using 1H nmr proved this to be the case and allowed the complete 
structure to be established. 
The 270MHz 1H nmr spectrum was assigned completely. Standard nmr 
methods were then used in conjunction with extensive application of 
negative nOe's which established the relative orientations of the various 
structural units, stereochemistry, and points of attachment of the 
substi tuents 50, 51 . The full structure as deduced by these studies is 
presented in -figure 2.3. 
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2.3 TRIOSTIN A 
The structural determinations of the triostin antibiotics were 
considerably easier than those described in the previous two sections for 
vancomycin and ristocetin A. Conventional amino acid analysis, after acid 
hydrolysis, identified most of the antibiotic components52, for example 
triostin A was composed of the following moles of amino acid per mole of 
antibiotic; serine 1.46, alanine 1.98 , dimethylcystine 1.05, methylvaline 
1.87. Ammonia (0 .29 moles ) was also isolated. In addition, UV absorption 
identified the presence of quinoxaline-2-carboxylic acid (2 moles) in all 
triostins and echinomycin-type antibiotics as being the only other 
component52. 
In order to obtain a better understanding of the mode of action of 
triostin A preliminary studies to determine the conformations in solution 
were performed53. The molecule has a two-fold axis of symmetry, therefore a 
single resonance only was observed for identical nuclei in the two halves 
of the molecule. The existence of two discrete conformers, with an energy 
barrier of 92 KJ.mole- 1 between them, was proposed from 1H nmr spectra. The 
population of the conformations was dependant upon solvent polarity and 
led to the conformer favoured in polar solvents (water, dmso, etc.) being 
labelled 'p', and that preferred in non-polar sol vents ( chloroform, 
benzene, etc.) as the n-conformer. Further extensive studies were 
performed54 to identify the precise nature of the conformers and to 
determine the differences between them that could account for the observed 
energy barrier. The conformation in solution of the related antibiotic 
echinomycin55 was determined using nmr spectroscopy, CPK model building 
and potential energy calculations. A similar approach was used for 
triostin A, apd comparison of the nmr chemical shift and coupling constant 
data of the p-conformer with echinomycin produced minor differences only. 
A similar parallel existed for the temperature variation and solvent 
effects of the amide NH protons. It was therefore proposed that triostin-p 
and echinomycin had very similar conformations in solution. A summary of 
the more significant findings of Kalman and co-workers ·is now presented. 
The quinoxaline H-3 proton chemical shifts (n, 9.61 6 ; p, 9.69 0 ) of 
both conformers were deshielded by around 1. 5ppm relative to the other 
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ring protons. The existence of an intramolecular hydrogen bond between the 
quinoxaline carbonyl group and H-3 was proposed to account for this and 
was based on comparable studies with model compounds. The quinoxaline 
system ring current was invoked as the cause for the low-field resonance 
positions of the ser-NH protons in both conformers. The ser Ja NH coupling 
' constant in triostin-p was 6.4Hz whereas for the n-form it was 8.4Hz; a 
significant change in orientation had occurred about the serine Ca -N bond. 
Mode l building studies for both conformers revealed that the serine a -CH 
and ~ -CH 2 groups can only point outwards from the peptide ring. A trans 
orientation was assumed for the ester linkage and since the serine ~ -CH 2 
resonance chemical shifts were similar for both of the triostin conformers 
and for echinomycin it was assumed to be so in all three antibiotics. In 
the absence of Ja NH coupling constants for the N-methylated residues, the 
' 
amide bonds of both conformers were assumed to be trans on the basis of 
a -CH chemical shift correlations with linear peptides, diketopiperazines 
and other model systems. Slight differences only were proposed between the 
conformers for the orientation about the cys-val peptide bond. The large 
valine vicinal a -CH- ~ -CH coupling constants (p, 10.0Hz ; n, 10.5Hz ) were 
indicative of hindered rotation of the valine side-chain in both 
conformers. Steric interference between the val- Y -methyl groups and the 
val-N-methyl was proposed which suggested that both of these groups were 
on the same face of the molecule, possibly the upper face as in 
echinomycin. The deshielding of the ala- a -CH protons in both conformers 
was ascribed to the proximity of the ser-CO, the two groups being closer in 
the n-conformer which experienced larger deshielding. Trans ser-ala 
peptide bonds were therefore proposed for both conformers. A major change 
in orientation of the alanine residue was apparent from the coupling 
constants; for triostin-p ala Ja ,NH 5.7Hz whereas for the n-conformer 
Ja , NH 9. OHz. · _ 
In accordance with other studies on disulphides the cross-bridge 
was assumed to have a dihedral angle (the ·angle between the cysteine 
methylene groups when looking along the disulphide bond) of 80°-90°. It 
was not possible to discriminate between the two possible chiralities 
(+90° and -90°) by nmr. 
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The cys J0 . ~ coupling constants were calculated from an ABX 
analysis of the multiplets for both conformers although no single rotamer 
could be found for either one which fitted the data. A flexible cross-
bridge was therefore proposed in each case. 
Upon addition of the lanthan ide shift reagent (lsr), Eu(fod) 3, the largest shifts were observed for triostin-n, in addition the equilibrium 
between the two conformers was displaced in favour of then-conformer. The 
binding of Eu3+ to triostin-n was evidently stronger than to triostin-p. 
From the magnitude of the shifts the site of complexation for the n-
conformer was deduced to be the ser-CO ( as in echinomycin), whereas in 
triostin-p multiple binding sites for Eu3+ prevented detailed analysis. 
Having appraised the data for each residue of the antibiotic, in 
each conformer, Kalman and co-workers were in a position to postulate the 
changes that would be necessary to account for the energy barrier of 
92KJ.mole- 1• Three possibilities were considered. 
(1) Rotation of a trans-N-methylated peptide unit through the ring. Two 
such conversions would be necessary to conserve the molecular 
symmetry. 
(2) Conversion of a trans amide bond to cis, again two such 
interconversions would be necessary. 
(3) Reversal in chirality of the disulphide bond. 
Molecular models were constructed using the partial conformational 
information derived earlier and including the additional constraints 
imposed by cycl isation and cross-bridge formation. The nmr spectra of 
triostin-p and echinomycin were so similar (although the lanthanide 
induced shift, LIS, data was at variance) that the overall ring 
conformation for these two antibiotics was· concluded to be the same. 
Similarly, despite considerable variations between the nmr spectra of 
triostin-n and echinomycin, on the basis of the LIS data it was concluded 
that these too had the same overall ring conformation. It was therefore 
proposed that the main difference between the two triostin conformers was 
the chirality of the disulphide bond. Additionally, in triostin-n an 
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intramolecular hydrogen bond between the quinoxaline-CO and the ala-NH, 
forming a seven-membered ring, was invoked to account for the low-field 
ala-NH resonance. Other differences observed between the two conformers 
were considered to be due to small conformational changes associated with 
the interconversion noted above. 
Al though it was not possible to determine whether either of the 
conformers studied was actually involved in binding to DNA it was observed 
0 that the proposed conformations placed the quinoxaline rings 10A apart; a 
distance suitable for simultaneous intercalation with DNA. It was further 
speculated that the ala-NH of triostin-p may be involved in determining 
the specificity of binding by hydrogen bonding to groups in the groove of 
DNA. This also accounted for the observed differences in specificity of 
binding between echinomycin and triostin-p which differ in the 
orientation of the ser-ala portion of the antibiotic. 
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3. THE BACTERIAL CELL WALL 
3. 1 INTRODUCTION 
The vancomycin-type antibiotics function by inhibiting synthesis of 
peptidoglycan56 (also called mucopeptide), the major structural component 
of the cell-walls of Gram-positive bacteria. These outer layers of a 
bacterium determine its response to the Gram stain which has been used as 
the basis for the classification of bacteria. 
The individual components of the bacterial envelope can be 
differentiated both structurally and functionally. The innermost layer, 
the cytoplasmic membrane, is the permeability barrier across which 
substrates must be transported, and is also the site of oxidative 
phosphorylation and chromosome attachment; it is responsible for the 
biosynthesis of wall and membrane polymers. The peptidoglycan is 
responsible for the mechanical strength of the bacterium. In Gram-positive 
bacteria the teichoic acids are the antigenic determinants, provide some 
of the sites of attachment for bacteriophages and may also play a role in 
· ion-binding and transport. In Gram-negative bacteria the 
lipopol ysaccharides have these functions. Both Gram-positive and Gram-
negative bacteria have the same basic structure of an inner cytoplasmic 
membrane surrounded by a wall containing the peptidoglycan, but the 
additional components and their arrangement in the walls are different 
(figure 3.1). In addition the walls of Gram-positive bacteria are 
significantly thicker than those of Gram-negative species. 
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3.2 PEPTIDOGLYCAN STRUCTURE 
In all bacterial species the peptidoglycan consists of a backbone of 
p -1,4-linked alternating units of the amino sugars N-acetyl-glucosamine (GlcNAc) and its 0-lactyl ether, N-acetyl-muramic acid (MurNAc). 
Projecting from the amino sugar backbone are short peptide chains in a 
species specific sequence. The most common of these consists of the four 
amino acids, L-alanine, D-glutamic acid, a diamino acid and finally D-
alanine (figure 3.2). In staphylococci the diamino acid is L-lysine while 
in Escherichia coli and all Gram-negative bacteria it is meso-
diaminopimelic acid (DAP). In some species the y-carboxylate of glutamic 
acid is amidated or substituted with an additional amino acid. The peptide 
chains are cross-linked from the carboxylate group of the terminal D-
alanine to the free amino group of the diamino acid either directly or by 
a short peptide bridge. The overall structure of a typical peptidoglycan 
is shown in figure 3.3 • 
., 
3.3 PEPTIDOGLYCAN BIOSYNTHESIS 
Synthesis of peptidoglycan can be divided conceptually into three 
stages. The first stage, catalysed on the inside of the cell by cytoplasmic 
enzymes, is the synthesis of the soluble peptidoglycan precursor uridine 
5 1-diphosphate-N-acetyl-muramylpentapeptide (figure 3.4). 
This step is followed by transfer of the N-acetyl-
muramylpentap~ptide (MurNAc-pentapeptide) and N-acetyl-glucosamine (GlcNAc) to a lipid carrier, c55-isoprenyl alcohol (figure 3.5) in the 
membranes, forming a subunit of the glycan polymer (figure 3.6). The 
membrane-bound disacchar ide pentapeptide is now modified in a species 
specific fashion. Such modification may include substitution of a carboxyl 
group on glutamic or diaminopimelic acid residues, or attachment of a 
peptide side chai~ (for example the pentaglycine chain attached to the 
lysine residue of the pentapeptide in Staphylococcus aureus (figure 3.6). 
In the last stage, the modified disaccharide-pentapeptide residue is 
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transferred to a glycan acceptor on the outside of the cell to form a 
linear peptidoglycan. 
Finally, the peptide chains of the linear peptidoglycan are cross-
linked in a reaction catalysed by a transpeptidase. The cross-bridge is 
formed between the carboxyl group of the penultimate D-alanine in the 
pentapeptide on one chain and an amino group in a nearby chain, for example 
that of the DAP residue ( figure 3. 7a). The analogous step for Gram-positive 
bacteria is shown in figure 3.7b. 
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4. NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY 
An understanding of the nuclear magnetic resonance (nmr ) phenomenon 
can be gained by reference to any suitable standard text [1]. However, it 
is worth emphasising certain points, especially relating to high-field 
pulsed Fourier transform nmr which has bee~ extensively used in the 
studies described later [2 J • 
4. 1 PULSED FT NMR 
Pulsed nmr involves the simultaneous excitation of all the protons 
in a molecule. A stronger radio-frequency is used for irradiation than 
that for conventional continuous wave nmr and to avoid total saturation of 
the energy levels it is applied for a very short time (typically 
microseconds). The return to equilibrium of the excited nuclear spins 
gives rise to what is termed free induction decay (FID) which corresponds 
to the nmr spectrum along a time axis instead of the usual frequency axis. 
Conversion to the latter is effected by application of the mathematical 
process of Fourier transformation. It is important to realise , therefore, 
that the FID and the conventional nmr spectrum are two representations of 
the same data set . Pulsed FT nmr has the advantage of enormous savings in 
time over continuous wave nmr and, since the data is accumulated rapidly 
in a digital form, many successive experiments may be performed on the 
same sample and the data f r om each one added together to provide 
significant improvements in the signal to noise ratio. 
By convention , the magnetic field direction , B0 , is te r med the z-
axis, the radio- frequency pulse is applied along the x-axis, and the 
[1] See Appendix 1 
[2] See Chapter 6 
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remaining dimension, in which the observe receiver is situated, is termed 
the y-axis. Thus only magnetization in the x-y plane can be detected with 
this arrangement. The Boltzmann distribution describes the equilibrium 
situation in which a slight excess of nuclei are in the lowest energy 
level which therefore produces a net magnetization along the direction of 
the magnetic field (the z-axis). The maximum signal therefore corresponds 
to a 90° perturbation of these nuclear magnetic vectors to the y-axis 
(figure 4.1 ). 
In optical spectroscopy an excited molecule returns by spontaneous 
emission to the ground state almost instantaneously, the excess energy 
being dissipated into the surroundings (the lattice) as heat. This process 
is not favourable for a nuclear spin, which is effectively insulated from 
the lattice. Instead they return to the ground state by an emission 
process (relaxation) taking seconds and involving interaction with the 
lattice and other magnetic fields. From the uncertainty principle the 
existence of the excited state for a long time produces sharp lines and 
enables equalisation (saturation) of the ground and excited levels to be 
attained by application of a strong secondary exciting field. 
The spin-populations return to equilibrium either by interaction 
with the environment, which is called spin-lattice or longitudinal 
relaxation and has a time constant T 1, or by interaction of proximal 
nuclear spins through a dipole-dipole effect, which is termed spin-spin or 
transverse relaxation and has a time constant T2• Short T1 values indicate 
the efficient return of the nuclear spins to equilibrium and T2 values. are 
never greater than T1• In order to relate these effects to the 
magnetization diagrams shown in figure 4.1 it is desirable to use what is 
known as the -rotating frame of reference. With the conventional cartesian 
axes the magnetization vectors are rotating in the x-y plane about the z-
axis at the Larmor frequency. If instead one considers the frame of 
reference (viz. the axes) rotating about the magnetic field at the Larmor 
frequency the magnetization vectors appear stationary. The spin-lattice 
relaxation can now be identified as the return of the vector from they-
axis to the z-axis in the y-z plane. Similarly, the spin-spin relaxation 
can be considered as a dephasing of the magnetization vectors in the x- y 
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plane which produces a reduction in the net effect observed in the y-
direction. Obviously these effects do not occur in isolation but both 
influence the return to equilibrium by varying degrees. The situation can 
be schematically represented as shown in figure 4.2. 
Finally, high-field nmr machines of 6.34 and 9.40T (270 and 400MHz 
H 1) were extensively used for tl'le studies described in Chapter 6, in 
preference to lower-field machines which were more accessible, because of 
a number of advantages associated with their use. The coupling constant is 
invariant with magnetic field strength, unlike the chemical shift. For 
example, upon comparing spectra taken at 100MHz and 400MHz a four-fold 
increase in the spectral width in Hz is involved for an equivalent 
chemical shift (ppm) range. Since multiplets occupy the same range in Hz 
at any field strength, assuming that undue resonance broadening has not 
occurred at increased field, it can clearly be seen that the spectrum will 
be significantly spread-out at higher field. Thus, spectral simplification 
is an important consequence of higher field instruments. In addition, 
chemical exchange studies [3] can benefit at higher field because the rate 
of exchange is proportional to the chemical shift difference in Hz between 
the resonances of the exchanging species. High field al so produces 
increased sensitivity since signal strength is proportional to the square 
of the magnetic field. One major disadvantage is that the wider spectral 
widths used at high field necessarily reduce the digitization; coupling 
. constants are therefore currently most accurately measured at lower field. 
4.2 DOUBLE IRRADIATION TECHNIQUES 
Apart from the non-selective pulse discussed above, the application 
of a selective second pulse can provide additional information . Resonances 
which are scalar-coupled can be identified, as can dipolar-coupled 
resonances. The pulse power can be varied according to the experiment and 
elaborate pulse sequences may be necessary in order to differentiate 
[3] See Section 4.3 
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4.2. 1 SPIN-DECOUPLING 
Spin-decoupling is by far the most common double irradiation 
technique. High pulse powers, greater than those necessary for saturation, 
are used in order to selectively .remove spin-coupling effects. A simple 
decoupling pulse can also give rise to effects such as transfer of 
saturation between chemically exchanging species, and nOe's, both of which 
are discussed below. 
4.2.2 THE NUCLEAR OVERHAUSER EFFECT 
The nOe is manifested by a change in peak intensity when two nuclei 
are close in space, and therefore dipolar-coupled, and one of them is 
saturated. If one considers two such nuclei which are not scalar-coupled 
the equilibrium situation can be represented by figure 4.3a. The direction 
of the nuclear spins are shown by the arrows and the transitions for each 
nucleus, A and X, which give rise to the resonance lines are indicated by W. 
At equilibrium the populations of energy levels 2 and 3 are considered to 
be equal (p), with a slight excess of population in level 1 (p+q) and a 
slight deficit in the highest energy level 4 (p-q). Peak intensity is 
proportional to the population differences of the energy levels between 
which transitions occur. Thus before perturbation of the spin system both 
nuclei have an intensity of 2q. Saturation of spin A causes equalisation 
of the populations between which transitions giving rise to the A 
resonance line occur. In other words levels 1 and 2 (p+1/2q), and levels 3 
and 4 (p-1/2q) are equalised. However, at this stage the intensity of 
nucleus X is still 2q ( figure 4.3b). The system as a whole is now perturbed 
compared to the equilibrium situation; the degenerate levels 2 and 3 are 
separated by a population difference of q, and the separation between 
levels 1 and 4 has been reduced from 2q to q. The system attempts to return 
to equilibrium, the usual single quantum transitions are too inefficient 
therefore the double quantum (level 4-1) or zero quantum (level 2-3) 
transitions are used. Considering the double quantum transition, w2, first (figure 4.3c); an amount of spin density, d, is transferred from level 4 to 
the ground state. The intensity of the X-resonance is now increased to 
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2q+2d, thus it is enhanced by 2d and is termed a positive nOe. Conversely, 
if the spin density, d, is transferred from level 2 via the zero quantum 
transition, W0 , to level 3 (figure 4.3d) then the intensity of the X-
resonance is reduced to 2q-2d. Thus it is decreased by 2d and is termed a 
negative nOe. 
The rate of build-up of an nOe has an r-6 dependence. The maximum 
homonuclear positive nOe is 50% whereas the maximum negative nOe is 100%. 
The nOe is critically dependent on the function Wtc, where W=2nv Hz (the 
Larmor frequency) and tc is the rotational correlation time (effectively 
the tumbling time). If the value of this function is above 1.12 a negative 
nOe is observed whereas below 1. 12 a positive nOe is observed. At exactly 
Wtc=1.12 no nOe is observed. In general large molecules, or small molecules 
in viscous solvents, exhibit negative nOe's whereas small molecules 
usually produce a positive effect. The magnitude and sign of the nOe can be 
manipulated by varying the temperature (larger and more positive nOe's at 
higher temperatures) or the solvent system (larger and more negative nOe's 
in viscous solvents). For Wtc far greater than 1.12 an effect termed spin 
diffusion becomes important. At long tc, especially with large molecules, 
excitation applied to one nucleus is no longer dissipated through 
molecular motion, but is instead transferred to neighbouring nuclei, 
causing their signals to decrease or disappear. Hence this effect is only 
observed in the negative nOe regime. In addition, spin diffusion can be 
rapidly spread throughout a molecule if either the irradiated proton, or 
one of the neighbouring protons is exchangeable with protons in other 
distant parts of the same molecule. However, the initial decay of 
magnetization is much more dependent on the local environment than the 
overall decay. 
4.2.3 DIFFERENCE SPECTRA 
Subtle changes in spectra are frequently difficult to monitor 
because of the initial complexity of the spectrum. A simple and rapid 
method of removing unnecessary information is to make use of difference 
spectra. A reference spectrum is accumulated in one block of computer 
memory whilst in another block the perturbed spectrum is collected. 
Subtraction of one set of data from the other produces a spectrum solely 
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of perturbed resonances which is far easier to interpret. Figure 6.16 is an 
example of an nOe difference spectrum, and figure 6.27 is that of a 
decoupling difference spectrum. 
4.3 CHEMICAL EXCHANGE 
The line shape of nmr signals is sensitive to chemical exchange 
processes and such spectra are also temperature dependent. The effect 
depends upon the rate of exchange compared with the nuclear spin time 
scale. If the exchange is slow, then the spectra of the separate species is 
observed. If the exchange is fast then a spectrum corresponding to the 
weighted mean of the individual spectra is observed but without 
significant line broadening. However, in the intermediate region broadened 
and averaged spectra are obtained. 
Quantitative kinetic and thermodynamic information can be obtained 
from line ;5hape analysis of a slow exchanging species which is slowly 
converted to the fast exchanging species, usually by an increase in 
temperature. The temperature at which the resonance lines, corresponding 
to the same nucleus in two environments, merge is called the coalescence 
temperature. The relatively complex nature of line shape analysis has 
prompted a number of approximate solutions, most of which require a 
knowledge of the coalescence temperature, Tc , and the shift difference, 
OvHz, between the resonances in question in the slow exchange region. The 
most useful of these are shown in figure 4.4. The energy barrier obtained 
from figure 4.4b is temperature dependent. 
4.3. 1 TRANSFER OF SATURATION 
If a nuclear species exists in two environments which are non-
equivalent then one would expect a change in the magnetization of site A 
to also be detectable at site B. The effect is observed only if the T1 in 
site B is not negligible compared with the lifetime of the nucleus in site 
B,. 
22 
, I 
I 
I 
Kcoal = TT 6 v = 2·22 6v 
r;- (a) 
Kcoal is the rate constant at the coalescence temperature 
- * - T -I llG = 19•14Tc (9-97+1og-S) Jmole (b) 6v 
llG * is the energy barrier for the process at the 
coalescence temperature 
FIGURE 4·4 Approximate equations for chemica I 
exc.h a nge pheno,n ena 
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5. PREVIOUS BINDING STUDIES ON VANCOMYCIN-TYPE ANTIBIOTICS 
The site of action of vancomycin-type antibiotics had been known for 
some time to be the cell-wall of Gram-positive bacteria57,59 but it was 
not until the extensive studies of Nieto and Perkins 60- 63 that the precise 
location of this interaction was determined. Vancomycin-type antibiotics 
inhibit the biosynthesis of the peptidoglycan of bacterial cell walls 
causing the accumulation of UDP-N-acetylmuramyl-peptide precursors. Using 
various peptidoglycan precursors and systematically changing each residue 
in turn Nieto and Perkins were able to identify the conditions necessary 
for complex formation as follows: 
(1) Residue 1 (C-terminal) must have D-configuration or be glycine, the 
carboxyl group must be free and in the anionic form, and the optimum 
side-chain length is a methyl group for vancomycin but larger side-m 
chains can be accorrt>dated with ristocetin (presumed due to steric 
crowding around the chlorine atom of ring 1 of vancomycin). 
(2) Residue 2 must also have the D-configuration or be glycine and the 
optimum side chain is a methyl group. The peptide N-terminus must be 
blocked, by acetylation or formylation, for complex formation. 
( 3) The L-configuration is preferred for residue 3 and the optimum 
affinity is found with L-lysine or L-ornithine. 
On the basis of their experimental evidence [1] it became clear that 
the primary site of attack for vancomycin-type antibiotics was the D-ala-
D-ala growth point of the bacterial cell wall. 
[1 J See table 5.1 
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Table 5. 1 Vancomycin and Ristocetin B Binding Data63 
Peptide 
Vancomycin 
AG 
Ristocetin B 
AG 
Change in Residue 1 
Ac 2-L-lys-D-ala-D-ala 
Ac2-L-lys-D-ala-gly 
Ac 2-L-lys-D-ala-D-leu 
Ac2-L-lys-D-ala-D-lys 
Ac 2-L-lys-D-ala-L-ala 
Ac-D-ala-D-ala 
Ac-D-ala-gly 
Change in Residue 2 
Ac 2-L-lys-gly-D-ala 
Ac2-L-lys-D-leu-D-ala 
Ac2-L-lys-L-ala-D-ala 
Ac-gly-D-ala 
Change in Residue 3 
Ac-gly-D-ala-D-ala 
Ac-L-ala-D-ala-D-ala 
N-Ac-L-tyr-D-ala-D-ala 
Ac-D-ala-D-ala-D-ala 
Free Amino Group 
L-lys-D-ala-D-ala 
-Ac-L-lys-D-ala-D-ala 
Other Peptides 
Ac-L-ala-gly-gly 
Ac-gly-gly-gly-gly 
Ac-L-ala-D-glu-gly 
150 35 . 1 
13 29.1 
o. 92 22. 5 
1.4 23.5 
N/C N/C 
2.0 24.4 
0.54 21.2 
9.4 28.3 
29 31.0 
N/C N/C 
1. 1 23. 0 
9.4 28.3 
31 31.1 
19 30.0 
5.0 26.7 
1.2 23.0 
47 32 . 2 
0.49 
o. 15 
48 
21. 7 
18.0 
32.3 
59 
2.2 
61 
10 
N/C 
7.2 
0. 19 
16 
5.8 
N/C 
4.9 
16 
22 
29 
13 
0.82 
19 
0.25 
0.08 
0.07 
Association constants (KA) measured in 104.1.mole- 1, 
free energy changes (AG) measured in KJ.mole- 1• 
No combination is indicated by N/C. 
32.8 
24.7 
32.9 
28.4 
N/C 
27.6 
18.7 
29.6 
27.0 
N/C 
26.7 
29.6 
30.4 
31.1 
29. 1 
22.2 
30. 1 
19.3 
16.5 
16. 1 
In order to determine the nature of the interaction between 
peptidoglycan precursors and vancomycin, electrophoresis was performed in 
the presence of various reagents 60 . In the presence of 1M sodium chloride 
or 10mM Ca 2+ or 85mM Mg2+ there was no sign of dissociation of the 
compound, which indicated that a simple ionic interaction was not 
involved, whereas in the presence of 8M urea almost complete dissociation 
of the complex occurred. Hydrogen bonding was therefore invoked as the 
25 
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major interaction. The two free amino groups of vancomycin were not 
thought to have a significant influence on complex formation 60 since upon 
N-acetylation or N-formylation binding still occurred, as monitored by 
antibacterial activity, although to a reduced extent. Aglucovancomycin, a 
form of the antibiotic with the sugar moiety removed, was al so found to 
retain antibacterial activity, indicating that the sugar moieties were not 
essential for activity but probably ·aided transport within the body. 
5. 1 VANCOMYCIN 
was 
The first direct study of the intermolecular interactions using nmr 
performed by Brown and co-workers 64 , 65 who monitored the peptide 
resonances and the methyl resonances of vancomycin upon binding. The 
complexity of the spectrum at 100MHz precluded detailed analysis and 
assignment, thus limited information only, of methyl group shifts and pH 
dependence of association constants was obtained. The most stable complex 
was formed in the pH4.0-7.5 region, being stabilised by a favourable 
electrostatic interaction (~ G0 :-5.9KJ.mole-1 ) between the terminal 
carboxylate anionic group of the peptide with the cationic group on the N-
methylleucine of vancomycin. Weaker complexes were found in the ranges 
pH2-4 and pH7.5-10.5. The acetyl methyl group was the only bound peptide 
methyl resonance to shift upon pH titration; about 7Hz at the pK of the 
amino groups (pK.-8), which suggested that this group was proximal to the 
vancosamine amino group. The leucine methyl groups were shifted 13Hz in 
the complex and this was pH independent between pH3.7-10.5, being 
apparently unaffected by most ionization states of the ionic groups. 
However, at pH2.2, the shift was reduced to 3Hz, which suggested that these 
two methyl groups were close to the peptide carboxyl. The thermodynamic 
parameters of complex formation were calculated as ~G0 -25.2KJ.mole- 1; 
~H0 -58.1KJ.mole- 1; ~S0 -24e.u. The bound shifts were found to be 
temperature independent indicating that they were probably due to ring 
current effects r ather than a conformational change. Experiments on the 
complex of aglucovancomycin with acet yl - D- ala-D-ala pr oduced a similar 
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pattern of bound shifts but reduced by about 75% compared with the 
vancomycin complex, implying a slightly modified binding site . The 
association constant was also reduced compared with vancomycin/Ac-D-ala-
D-ala by about one order of magnitude. Further confirmation of the results 
of Nieto and Perkins was evidenced by a series of experiments in which 
peptide residues were systematically changed to investigate specificity 
of the binding site. The position of the bound resonance of the C-terminal 
alanine was found t? be invariant with changes in other parts of the 
peptide, suggesting that it was enveloped in a pocket in the receptor site, 
a view supported by the reduction in the association constant upon 
substituting a larger group for the methyl side-chain. 
The first high field nmr study was performed by Williams and 
Kalman37 using a 270MHz machine. The spectra of aglucovancomycin and 
vancomycin were assigned in dmso-d6 in order to retain exchangeable proton 
resonances. By this time all of the component parts of vancomycin had been 
identified although there was little evidence to suggest the most probable 
way in which they were coordinated to one another. Using chemical shift 
and nOe evidence Williams and Kalman were able to tentatively suggest a 
structure in which all the residues were assigned approximate positions in 
the molecule al though four of the six secondary amide bonds were not 
identified. Further details of their structural studies are presented 
elsewhere [2] • Preliminary studies using vancomycin and Ac-D-ala-D-ala 
( 1: 1) in dmso-d6 produced a complex, as evidenced by selective shifting and 
broadening of certain resonances (table 5.2). 
[2] See Section 2. 1 
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Table 5.2 Vancomycin/Ac-D-ala-0-ala (1:1) in dmso-d5 (270MHz) 
Shifts Upon Binding (70°C) 
Proton Shift(Hz) Proton Shift (Hz) 
a3 +51 d 
-19 
b 
-36 hh +18 
f +31 cc +18 
S4 +27 a5 +15 
S5 +23 a 
- 14 
S2 +13 
Downfield shifts are positive. 
A binding site was sketched out on the assumption that the protons 
whose resonances were most perturbed and selectively broadened were those 
associated most closely with the complexing of Ac-D-ala-D- ala. The 
downfield shifts of the N-methylleucine N-Me (hh) and the a -CH resonances 
(s4, s 5, cc) were ascribed to the possible formation of a zwitterionic salt 
bridge between the carboxyl group of the peptide and the N-methylleucine 
of the antibiotic. In addition, upon cooling to 45°C the N-methylleucine N-
Me was shifted downfield (60Hz) to a position close to that found in 
aglucovancomycin, in which it was known to be protonated64• From the data 
it was also suggested that protons f,b,s 2 and a3 were involved in the 
binding site which would indicate a cleft, between the triaryl system and 
the biphenyl system, along which the N-terminal end of the peptide 
substrate was bound. The previously reported 64 shielding of the C-terminal 
alanine methyl group was also confirmed. Shortly after this study 
Sheldrick and co-workers published38 the x-ray structure of a crystalline 
degradation product (GDP-I) of vancomycin in which the primary amide had 
been hydrolysed to a carboxyl. On the basis of a CPK model, built with 
reference to the x-ray data and the previous nmr studies , a more precise 
binding site was proposed involving three hydrogen bonds between the 
antibiotic and the peptide. This arrangement is shown schematically in 
figure 5. 1 and the model is shown in figure 5.2. Convert and co-workers 66 
recognised that the crystal structure of GDP-I did not allow for any 
interaction between the peptide carboxyl and the 
vancomycin. Having previously found 64 a contribution of 
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zwitterionic salt bridge between these two groups upon complex formation 
0 they proposed that the positively charged N-Me protons, which are about 9A 
distant from the peptide carboxyl according to the x-ray study, could 
0 reasonably be moved to within 5A of the peptide carboxyl simply by 
rotation about the flexible leucine side-chain (figure 5.3). Such a 
modification could account for the shifts of the leucine methyl groups, 
the aspartic-NH and aspartic methylene protons. In addition, upon 
increasing the length of the peptide backbone by adding a diacetylated L-
lysyl residue to the N-terminal alanine of D-ala-D-ala, a significant 
upfield shift, of 28Hz, was observed for the C-3 methyl group of the amino-
sugar vancosamine, indicating a possible sugar-peptide interaction. 
5.2 RISTOCETIN A 
The specific nature of the binding site of the antibiotic ristocetin 
A has only recently been studied, by Kalman and Williams 67 using 270 and 
360MHz proton magnetic resonance spectra. Assignment of the spectrum of 
ristocetin A bound to Ac-D-ala-D-ala was simplified by the fact that slow 
exchange conditions [ 3] prevailed for most resonances at temperatures 
less than 4o 0 c in dmso-d6. This was due to the high barrier to 
dissociation 14 (rv75KJ.mole- 1 ) and the large shift differences suffered by 
some of the protons. Addition of 0.5 molar equivalents of ristocetin A to 
peptide in dmso-d6 solution gave rise to two sets of resonances due to 
free and bound peptide; the correlation being made between them by 
transfer of saturation experiments [ 4 J • The two alanine methyl groups 
were found to be considerably shielded (0.35 and 0.89ppm), the C-terminal 
methyl being the most shielded was presumed to lie over one of the 
aromatic rings of the triaryl system such that it experiences a 
significant ring current effect. The downfield shift (0.33ppm) of the 
proton (cc) attached to the same carbon as the free amino group was 
[3] See Section 4.3 
[4 J See Section 4.3. 1 
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FIG URE 5·3 Proposed rotation of vc1ncomycin leucine residue 
ascribed to the protonation of this amino group after the addition of the 
acidic peptide (N.B. this grouping was presumed un-protonated in free 
vancomycin on the basis of shift analogies with aglucovancomycin upon the 
addition of base to deprotonate the amino group). From the small changes 
observed in J0 NH for the free and bound antibiotic it was clear that no • 
major conformational change, such as peptide bond rotation or cis-trans 
isomerization, had taken place upon ·binding. The main evidence used to map 
out the binding site of ristocetin A with the cell wall peptide analogue 
Ac-D-ala-D-ala was obtained from the temperature dependence and chemical 
shifts of NH resonances and intramolecular and intermolecular nOe's of the 
complex. From a study of the free peptide it was shown that secondary amide 
NH protons exposed to solvent have temperature coefficients of the order 
-5 to -6 X 10-3. Comparing this value with the temperature coefficients of 
the bound NH protons it was clearly evident that the N-terminal NH proton 
( !::.. o/ l::.. T = -6.2 X 10-3) was exposed to solvent, whereas the C-terminal NH 
proton ( !::.. o I !::.. T = -1. 5 X 10-3) was not. A hydrogen bond was therefore 
postulated between the latter and ristocetin A. Similarly, the reduced 
accessibility of the ristocetin a 1 proton to solvent, and the considerable 
downfield shifts of the NH proton resonances a4 (4.64ppm), a5 (2.42ppm) and 
a 3 (1.45ppm) upon binding was in accord with the existence of hydrogen 
bonds between these protons and the peptide. On the basis of the above data 
it was proposed that in the ristocetin A/peptide complex the antibiotic NH 
proton a 1 and the pocket of NH protons formed by a3-a5-a4 act as H-bond 
donors to respectively the acetyl-CO and the carboxylate group of the 
peptide, and that the antibiotic ring 2 carbonyl is H-bonded to the 
peptide C-terminal NH proton . An additional interaction between the 
peptide carboxylate group and the antibiotic -NH~Me group was proposed on 
the grounds of the Coulombic stabilization of the complex and the 
additional H-bonding. The arrangement is illustrated schematically in 
figure 5.4 and in a CPK model in figure 5.5. Further evidence for this model 
was provided by the observation of intermolecu~ar nOe's between protons of 
the antibiotic and the peptide in the complex (table 5.3, nOe's 1,2,3 and 7) . 
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Table 5.3 Ristocetin A/Ac-D-ala-D-ala nOe's (negative) 67 
nOe no . Proton Irradiated 
1 ala 2CHb 
2 ala 1Meb 
3 ala 2Meb 
4 ala 1NHb/i 
5 ala-Ac-Meb 
6 a4 
1 S6 
Subscript b denotes bound resonances 
nOe' s Observed 
f ,S6 
d 
f 
ala2CHb 
ala 2NHb 
i/ala 1NHb 
ala 2CHb 
From CPK models it was evident that the peptide protons involved in 
these intermolecular nOe's were in contact with, or close to, protons of 
the antibiotic, as shown in figure 5.6. This model was found to accomodate 
all the data, including the large upfield shift (0.89ppm) of the C-terminal 
alanine methyl group , which would have to reside immediately over the face 
of the aryl ring 2. Finally parallels were drawn between the proposed 
binding of ristocetin A to Ac-D-ala-D-ala and the mode of action of 
vancomycin [5] ; it was noted that three of the hydrogen bonds proposed in 
the ristocetin A model ( viz. involving NH protons a 1 and a3 of the 
antibiotic and the C-terminal alanine NH of the peptide) had also been 
proposed in the vancomycin model. 
[5] Discussed in Section 5.1 
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6. PRESENT STUDIES 
6.1 VANCOMYCIN - REFINEMENT OF STRUCTURE AND BINDING SITE 
The binding model (figure 5.1) of vancomycin and dipeptide proposed 
on the basis of x-ray data38 of the vancomycin derivative CDP-I, 
independent nmr studies37, 64 •65 and CPK model building38 has been 
generally accepted as correct . I now propose to show that it omits further 
important interactions and that the structure of vancomycin, as deduced 
from the crystal study of CDP-I, is incorrect. 
Earlier studies on vancomycin37 had led to the assumption that 
commercial samples of vancomycin in dmso-d6 were not protonated on the 
terminal N-methylleucine residue. This was based on the observation that a 
number of protons which shift upfield on deprotonation of the N-
methylleucine function of aglucovancomycin also suffer an upfield shift 
in vancomycin relative to protonated aglucovancomycin. However, striking 
as these analogies in chemical shift changes are, the conclusion must be 
incorrect since commercial samples of vancomycin hydrochloride give 
aqueous solutions with pH.-.,4. The N-methyl amino group has a pKa.-.,7.261 and 
must therefore be protonated in dmso-d6 solutions. This point has been 
reinforced by comparing the chemical shifts in dmso-d6 at 70°c of the N-
methyl protons hh and the a -CH proton cc respectively of the N-
methylleucine residue in ( a) aglucovancomycin hydrochloride (2.65 and 
3.99ppm) (b) ~glucovancomycin base (2.42 and 3.30ppm) and (c) commercial 
vancomycin hydrochloride (2.42 and 3.80ppm). Thus the same chemical shifts 
found for the N-methyl protons in aglucovancomycin base and commercial 
vancomycin are not due to a lack of nitrogen protonation in the latter 
case, since for this compound proton cc is much nearer in chemical shift to 
its position in aglucovancomycin hydrochloride than in aglucovancomycin 
base . The obvious · conclusion, therefore, is that the chemical shift 
differences between cases (a) and (c) ar e due to a conformational change 
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between aglucovancomycin and vancomycin hydrochlorides which involves 
movement of the fleJible N-methylleucine residue. Further support for the 
mobility of this side-chain is provided by the observation that the only 
large chemical shift difference ( < 0.2ppm) between agl ucovancomycin and 
vancomycin hydrochlorides, for a CH or CONH proton, is for a4 (8.67 and 8.00ppm respectively). Furthermore , in the spectrum of vancomycin 
hydrochloride, protons cc and a4 give very broad resonances relative to 
those found in the spectrum of aglucovancomycin hydrochloride, and 
resonance s 4 is no longer split by coupling to a4 (9Hz in aglucovancomycin 
hydrochloride). 
If a conformational change was involved upon binding then 
monitoring the longitudinal relaxation times of free vancomycin, table 6.1, 
and comparing this data with that of vancomycin complexed to Ac-D- ala-D-
ala, table 6.2, one ought to be able to identify those portions of the 
antibiotic proximal · to peptide. Unfortunately, the difficulties 
encountered from overlapping resonances, exchange broadening upon 
complexation and the somewhat random changes observed in T 1 prevented 
meaningful analysis of the changes observed. 
I 
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Table 6 . 1 Vancomycin longitudinal relaxation times ( s) . 
Resonance I1 Resonance I1 
t 1. 11 z 0 ,54 
V 0.99 f 0.52 
kin o. 96 bb 0 .50 
a 0.95 X 0.50 
S1 o. 92 a2 0.49 
S2 0.92 a3 0.49 
C 0.90 a5 0.47 
1 o. 88 a6 0,47 
b o. 86 hh 0.44 
d 0 .82 ii/ jj 0.44 
g 0.80 a1 0.40 
I S5 o. 80 gg 0.38 
I I 
S4 0.71 S6 0.38 
S3 0,67 hi j 0.32 
i o. 65 ff 0.29 
a4 0.61 0 0.25 
m 0.61 aa/ee 0.22 
y 0.54 
Data recorded in dmso-d6 at 45°c (270MHz) 
Ill 
Table 6.2 Vancomycin/Ac-D-ala-D-ala (1 :1 ) 
Longitudinal Relaxation Times ( s) 
Resonance 
.I 1 Resonance 
.I 1 
S1 1. 55 ala 1NH/ ala2NH 0.63 
S2 1. 55 bb 0.63 
t 1. 28 z 0.62 
g 1 • 21 S4 0.61 
r 1. 20 S5 0.61 
kin 1. 19 X 0.53 
V 1. 04 b 0 . 48 
f 1. 00 a1 0.47 
C o. 95 a6 0.47 
S3 o. 88 gg 0.43 
1 0.88 ala 1Me/ala2Me 0.43 
al a-Ac-Me o. 84 a 0.40 
d o. 77 0 O. 39 
i 0. 75 ii/ jj 0.37 
a2 0.64 ff 0.33 
y 0.63 
Data recorded in dmso-d6 at 45°c (270MHz). 
In addition Convert and co-workers 66 recognised that important 
Coulombic interactions known to exist64 between the peptide carboxylate 
group and the protonated N-methyl group of the vancomycin N-methylleucine 
side chain could not be accounted for by this model. They therefore 
proposed the minor modification entailing rotation of the flexible 
leucine side chain from its position as indicated by the x-ray data of 
CDP-I to one in which the distance between the groups in question was 
approximately halved (figure 5.3). 
In the related antibiotic ristocetin A the aglycone structure51 is 
similar to vancomycin except that the iso-asparagine and N-methylleucine 
residues are replaced by a biphenyl ether unit. However, the amide bonds 
are retained in the same relative positions to those found in vancomycin 
and it also has a primary amino group in a similar position to that of the 
N-methyl function of vancomycin. It therefore seemed reasonable that one 
would expect the respective binding sites of these two antibiotics to be 
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srmilar. The binding site of ristocetin A67 was found to involve a 
favourable interaction between the peptide carboxylate and the primary 
amino function mentioned above. In addition, hydrogen bonds were proposed 
between four of the six secondary amide NH protons of the antibiotic and 
the peptide. A further hydrogen bond was invoked from the peptide C-
terminal NH proton to the antibiotic . This last hydrogen bond and two of 
the four from the antibiotic had previously been proposed in the analogous 
binding site of vancomycin. The remaining two hydrogen bonds involved NH 
protons proximal to ring 3 of ristocetin A thus forming a pocket of NH 
protons around the peptide carboxylate anion. The analogous two NH protons 
of vancomycin being on the 'rear face' or the 'side' of the molecule 
(according to the structure derived from the x-ray data of CDP-I) could 
not conceivably be involved in the binding site unless a major 
conformational change had occurred. 
The binding of ristocetin A with Ac-D-ala-D-ala is well defined 
because in dmso-d6 at temperatures below 4o 0 c, most of the resonances are 
in slow exchange, on the nmr timescale, with their free components which 
allowed direct observation of the bound state. In particular, the 
resonances of the secondary amide bonds were assigned for both bound and 
free components; those protons which shifted markedly downfield upon 
complexation were clearly involved in hydrogen bond formation . In 
contrast, vancomycin is in intermediate exchange with Ac-D-ala-D-ala, even 
at 19°c ( just above the freezing point of dmso-d6 ), which means that an 
averaged view of the bound and free components is obtained. In order to 
simplify interpretation of the information contained in the spectrum of 
vancomycin complexed to peptide it was decided to seek experimental 
conditions where slow exchange prevailed. 
It was known from the work of Nieto and Perkins that the complex of 
vancomycin with the tripeptide Ac 2-L-lys-D-ala-D-ala had an association 
constant approximately two orders of magnitude greater than that with the 
dipeptide Ac-D-ala-D-ala which had been used in all of the high-field nmr 
studies so far performed in dmso-d6. It was therefore considered 
worthwhile to perform experiments using Ac2-L-lys-D-ala-D-ala, the 
synthesis of which is outlined below. 
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6.1.1 SYNTHESIS OF AC 2-L-LYSYL-D-ALANYL-D-ALANINE 
In general, polypeptides are constructed by reaction of the N-
terminus of an amino acid with the free carboxylate of the next amino acid 
in the sequence (with suitable protection of the carboxylate and amino 
groups respectively). The strategy for the synthesis of Ac2-L-lys-D-ala- D-
ala is shown in figure 6.1. 
(1) Protection of D-ala-NH2 : The most commonly used protecting groups 
for amino functionalities are t-butyloxycarbonyl (t-BOC) or 
carbobenzoxy (CBZ); the former was used in this case. The 
traditional reagent used in this reaction 
butyloxycarbonylazidoformate68 but in view of its 
is t-
explosive 
tendencies at 70°-so 0 c it was decided to use the more stable reagent 
t-butyloxycarbonyl-oxyimino-2-phenylacetonitrile (t-B0C-0N) 69. The 
free amino acid D-alanine was reacted with t-BOC-ON ( scheme 6. 1), 
and the resulting t-BOC-D-ala was separated from the oxime by 
extraction with a water/ethyl acetate mixture. Acidification, 
further extraction with ethyl acetate, followed by crystallisation 
from ethyl acetate/n-hexane produced a crystalline product which 
was recrystallised in good yields. 
(2) Protection of D-ala-COOH: The benzyl ester is the preferred 
protecting group for carboxylates and can be prepared by incubating 
the amino acid in benzyl alcohol and polyphosphoric acid70 at 90°c 
for several hours. Extraction with ether, adjustment of the aqueous 
phase to pH10 with base, further extraction with ether followed by 
treatment with dry hydrogen chloride gas results in precipitation 
of the benzyl ester hydrochloride, usually as a crystalline solid. 
However~_with D-alanine an oil was obtained , the proton nmr spectrum 
of which showed minor splitting (2Hz) of each line of the methyl 
doublet indicating that racemization had probably occurred . It was 
therefore decided to prepare the p-toluene sulphonic acid salt of 
the benzyl ester7 1 since crystalline products result with most 
amino acids. The benzene sulphonic acid serves as a catalyst , in lieu 
of hydrogen chloride, for the direct esterification of amino acids 
in benzyl alcohol. The use of p-toluene sulphonic acid renders the 
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amino acid soluble in excess benzyl alcohol as its benzene sulphonic 
acid salt. Water formed during the esterification process is removed 
by azeotropic distillation. The need for both large excesses of 
benzyl alcohol and high temperatures to remove the water of 
reacti on , in order to achieve a favourable equilibrium, is thereby 
avoided. In addition, since the temperature of the reaction mixture 
never exceeds so 0 c the danger of racemization of optically active 
amino acids and the occurrence of appreciable decomposition of the 
product is avoided. 
Azeotropic distillation of D-alanine in benzene with molar 
equivalents of p-toluene sulphonic acid and benzyl alcohol, was . 
performed using a Dean-Stark tube (scheme 6.2) . Upon completion of 
the reaction, dry diethyl ether was added to the cold 
mixture; crystallisation occurred upon chilling 
reaction 
in ice. 
Recrystallisation from methanol/diethyl ether gave a good yield of 
D-ala benzyl ester p-toluene sulphonic acid salt. The free base was 
released by dissolving the salt in base, extracting into diethyl 
ether, and adding petroleum ether (boiling range 40° to 60°C) to 
crystallise in reasonable yields. 
(3) Protection of L-lys-(NH2 )2 : In the final tripeptide L-lysine will 
be di-N-acetylated; it therefore seemed reasonable to protect the 
amino groups by acetylation from the beginning. However, reaction of 
L-lysine hydrochloride with aqueous acetic anhydride under basic 
conditions produced a mixture which was non-extractable with 
organic solvents, being soluble only in aqueous solution. In view of 
this shortcoming it was considered simpler to use the t-BOC group 
which had already been successfully used to protect the amino group 
of D-alanine; acetylation could be performed on the completed 
tripeptide. Although the same procedure was employed as that which 
was successful with D-alanine (except two-molar equivalents of the 
t-BOC-ON reagent were necessary for the dibasic lysine) it was not 
possible to isolate pure · di-t-BOC-L-lysine . In order to avoid 
further delay in the synthesis of the target tripeptide it was 
decided to purchase L-lysine which was di-N-protected with the 
carbobenzoxy group. 
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(4) Activation of L-lys-COOH : In order to facilitate the coupling of N-
protected lysine to C-protected alanine it was desirable to 
activate the carboxylate group of the former by ester formation. The 
di-CBZ-L-lysine was reacted with N-hydroxysuccinimide72 in the 
presence of dicyclohex ylcarbodiimide ( scheme 6.3). The resultant 
urea was removed by filtration to give a clear solution which upon 
rotary-evaporation gave an oil. The succinimide ester was readily 
crystallised in · good yield by the addition of diethyl ether and 
methanol. Further purification was unnecessary. 
(5) Protection of D-ala-D-ala-COOH: In .order to reduce the number of 
steps in the synthesis it was decided to use the readily available 
dipeptide D-ala-D-ala as one of the starting materials. The 
carboxylate group was protected utilising the p-toluene sulphonic 
acid salt of the benzyl ester in much the same manner as that used 
successfully with the single amino acid D-alanine [1]. 
(6) Coupling of L-lys to D-ala: Trial coupling of di-CBZ-L-lys 
succinimide ester to D-ala benzyl ester was effected by combining a 
solution of the former in 1,2-dimethoxyethane with a solution of the 
latter in aqueous sodium hydrogen carbonate (scheme 6.4). Immediate 
precipitation of the dipeptide resulted, with good yields and 
purity. 
(7) Coupling of L-lys to D-ala-D-ala : The free base of D-ala-D-ala 
benzyl ester proved difficult to isolate using the procedure 
outlined above in (2) for D-alanine. The reaction was therefore 
performed using the p-toluene sulphonic acid salt of the benzyl 
ester which was readily available. A solution of the activated 
lysine moiety in 1,2-dimethoxyethane was added to a weakly basic 
solution of the C-protected D-ala-D-ala residue. Immediate 
precipitation of a crystalline solid ensued which upon examination 
by nmr spectroscopy proved to be the required protected tripeptide. 
The regenerated N-hydroxysuccinimide and p-toluene sulphonic acid 
remained in solution. 
[1 J See (2) above. 
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(8) Deprotection of' L-lys-D-ala-D-ala : The benzyl ester and the two 
benzyloxycarbonyl protecting groups were readily removed by 
hydrogenation in the presence of 10%Pd/C catalyst. Reaction was 
allowed to proceed for several hours to ensure that hydrogenation 
was complete. The reaction mixture was then filtered to remove the 
catalyst and rotary-evaporated at 70°c to yield the free tripeptide 
as an oil which was not purified further. 
(9) Acetylation of' L-lys-D-ala-D-ala : The oily residue of the free 
tripeptide from the hydrogenation was dissolved in a minimum of 
water to which was added an excess of acetic anhydride. The reaction 
mixture was stirred for two hours, the solvents were then removed by 
rotary-evaporation ~t 70°c to give an oil. Purification of this oil 
of Ac2-L-lys-D-ala-D-ala proved to be something of a problem. Ion-
exchange was performed to remove trace amounts of mono-acetylated 
tripeptide, Dissolving the Ac2-tripeptide oil in ethanol and 
inducing crystallisation by the addition of diethyl ether to reduce 
the solubility was the most successful method. Reduced yields were 
obtained because of the difficulty in harvesting the crystals which 
were very soluble in ethanol; an excess of diethyl ether was 
necessary throughout. 
6.1.2 VANCOMYCIN/AC-D-ALA-D-ALA BINDING STUDIES 
The proton nmr spectrum at 100MHz of vancomycin complexed to Ac2-L-
lys-D-ala-D-ala in dmso-d6 at 19°c still exhibited intermediate exchange 
characteristics. In view of the fact that the rate of chemical exchange is 
dependent upon the shift difference in Hz between the bound component and 
free component resonances a spectrum at 270MHz was also taken. 
Unfortunately intermediate exchange conditions still prevailed and an 
alternative approach was therefore necessary. The problem of obtaining 
slow exchange was finally overcome by using dms9-d6 solutions containing 
-30% carbon tetrachloride, 'the mixed solvent system being employed to 
decrease the unimolecular rate constant for dissociation of the complex by 
reducing the freezing point (to less than o0 c) and in addition by 
inhibiting the breaking of hydrogen bonds present in the complex because 
of the increased lipophilic nature of the solvent. 
40 
(8) Deprotection of L-lys-D-ala-D-ala : The benzyl ester and the two 
benzyloxycarbonyl protecting groups were readily removed by 
hydrogenation in the presence of 10%Pd/C catalyst. Reaction was 
allowed to proceed for several hours to ensure that hydrogenation 
was complete. The reaction mixture was then filtered to remove the 
catalyst and rotary-evaporated at 70°c to yield the free tripeptide 
as an oil which was not purified ·further. 
(9) Acetylation of L-lys-D-ala-D-ala : The oily residue of the free 
tripeptide from the hydrogenation was dissolved in a minimum of 
water to which was added an excess of acetic anhydride. The reaction 
mixture was stirred for two hours, the solvents were then removed by 
rotary-evaporation ~t 70°c to give an oil . Purification of this oil 
of Ac2-L-lys-D-ala-D-ala proved to be something of a problem. Ion-
exchange was performed to remove trace amounts of mono-acetylated 
tripeptide. Dissolving the Ac2-tripeptide oil in ethanol and 
inducing crystallisation by the addition of diethyl ether to reduce 
the solubility was the most successful method. Reduced yields were 
obtained because of the difficulty in harvesting the crystals which 
were very soluble in ethanol; an excess of diethyl ether was 
necessary throughout. 
6.1.2 VANCOMYCIN/AC-D-ALA-D-ALA BINDING STUDIES 
The proton nmr spectrum at 100MHz of vancomycin complexed to Ac2-L-
lys-D-ala-D-ala in dmso-d6 at 19°c still exhibited intermediate exchange 
characteristics. In view of the fact that the rate of chemical exchange is 
dependent upon the shift difference in Hz between the bound component and 
free component resonances a spectrum at 270MHz was al so taken. 
Unfortunately intermediate exchange conditions still prevailed and an 
alternative approach was therefore necessary. The problem of obtaining 
slow exchange was finally overcome by using dmso~d6 solutions containing 
.-30% carbon tetrachloride, the mixed sol vent system being employed to 
decrease the unimolecular rate constant for dissociation of the complex by 
reducing the freezing point (to less than o0 c) and in addition by 
inhibiting the breaking of hydrogen bonds present in the complex because 
of the incr eased lipophilic nature of the solvent. 
40 
\ 
I 
\' 
.I 
I 
0 
~/'--N ~ H 
0 
~ 
0 
NH_ l ~ /OH y ~., y + 2 CH 3COOH 
H 0 0 
<N,N'-Ac2 -L-fys- D-ala -D-ala) 
Depr:::: te ctic n & acetylati on of Jys-ala-ala 
SCHEME 6·5 
\ 
1 1 
II 
Upon cooling a solution of vancomycin and Ac-D-ala-D-ala (...-...1:1) in 
the above solvent mixture to -1°C the complex goes into slow exchange with 
its free components at 270MHz. By means of variable temperature and spin 
decoupling studies it has been possible to assign the vast majority of the 
proton resonances both in the free state and in the complex for 
aglucovancomycin and vancomycin. From figure 6.2 it can be clearly seen 
that, with the exception of exchangeable protons, none of the resonances of 
aglucovancomycin have a shift greater than 0.1ppm in the temperature range 
10°-90°c. However, since no marked shifts were observed (figure 6.3) after 
the addition of one molar equivalent of Ac-D-ala-D-ala it would appear 
that complex formation does not occur in dmso-d6 solution at the natural 
pH of aglucovancomycin (pH...-...2.5). The addition of sufficient base (sodium 
methoxide in dmso-d6 solution) to deprotonate the carboxylate groups and 
the N-methyl group produced large shifts of many resonances (figures 6.4 
and 6.5). In addition, notable shifts upon the addition of peptide are 
shown in table 6.3 relative to the chemical shifts in the same solution at 
75°c. 
Table 6.3 Aglucovancomycin/Ac-D-ala-D-ala (...-...1: 1) 
Shifts Upon Binding (ppm) 
Resonance Shift Resonance Shift 
ala 1Me -0. 66 S4 +O. 28 
ala 1NH +0. 61 hh +0.25 
cc +0.59 S5 +0. 21 
a2 +O. 56 S3 +O. 21 j 
-0.47 ii/jj 
- 0. 20 
ala2NH +O. 44 h 
-0. 19 
83 +O. 33 t 
-0. 19 
a1 +0. 33 a 
-0. 19 
- b 
-0. 31 f +O. 17 
ala2CH +0. 29 ala2Me -0. 17 
Data recorded in dmso-d6/30%CC1 4 solution containing NaOMe 
at o0 c, shifts relative to resonance positions in the 
same solution at 75°c (270MHz) . 
Lowfield shifts are positive. 
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The most striking features in the spectrum are two resonances, one 
at each extreme of the spectrum, in analogous positions to those found in 
the ristocetin A/Ac-D-ala-D-ala slow exchange complex. The high field 
resonance at 0.51 ppm was readily assigned from the temperature variation 
studies as being the ala 1Me which is situated over the face of an aromatic 
ring and hence is greatly ring-shielded. The low-field resonance, however, 
was not as readily identified since it sharpened from the base-line noise 
at its bound resonance frequency (11.72ppm) and was therefore not followed 
with temperature variation. The resonance was found to be exchangeable 
upon the addition of deuterium oxide (D 20) and it was speculated that it 
could be the analogous secondary amide proton to that of ristocetin A, 
which was also found at a remarkably low-field position (11.83ppm) . Of the 
remaining shifted resonances several (cc , j, hh and h) can be ascribed to 
deprotonation of the N-methyl function of the N-methylleucine residue. The 
downfield shifts of cc and hh must be due to a conformational change since 
deprotonation would normally produce upfield shifts. However, downfield 
shifts of both of these resonances are observed over the same temperature 
range in the absence of peptide al though to a lesser extent. It is 
therefore unlikely that salt-bridge formation occurs with 
aglucovancomycin, especially not at pH8. The other resonances are 
presumably shifted because a change has occurred in their environment, 
either involving a direct effect with the peptide (or antibiotic, as the 
case may be) or from an induced conformational change upon binding. In 
view of the fact that the full binding site is not involved in the 
aglucovancomycin complex (as evidenced by the fact that complex formation 
only occurs under conditions of pH where a zwitterionic salt bridge, known 
to exist in the vancomycin complex, cannot be formed) the studies were 
continued using vancomycin. 
A temperature variation study of the vancomycin resonances is 
presented in figure 6.6. On comparing the most shifted resonances ( table 
6.4) with those of aglucovancomycin (table 5. 3) a marked similarity is 
noted both in the resonances affected and in the magnitude of the shift . 
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Table 6.4 Vancomycin/Ac-D-ala-D-ala ( 1 : 1) 
Shifts Upon Binding (ppm) 
Resonance Shift Resonance Shift 
ala 1Me -0. 66 ala2Me -0. 25 
cc +O. 57 ala2CH +0. 24 
a2 +O. 54 t 
-0. 23 
S4 +O. 48 ala2NH +0. 23 
b 
-0. 45 d 
-0. 22 
ala 1NH +O. 40 ala 1cH -0. 22 
a6 +O. 36 S6 +0. 21 
f +O. 35 ii/ jj 
-0. 20 
a1 +O. 34 a 
-0. 19 
r 
-0. 33 ff 
-0. 17 
S5 +O. 27 hh +0. 15 
Data recorded in dmso-d6/30%CC1 4 solution at 1°c, 
shifts relative to resonance positions in the same solution 
at 95°c (270MHz). Positive shifts are downfield. 
One interesting feature that perhaps is not evident from the data as 
presented is that the amide protons a3, a4 and a5 were broadened by 
chemical exchange to such an extent that it was hot possible to identify 
their bound positions at this stage. Double irradiation of the low field 
(11. 73ppm) exchangeable resonance produced only a slight change in the 
shape of the peak at 5.41ppm, a shoulder becoming more prominent. However, 
irradiation of this shoulder produced ----60% increase in the peak height of 
the resonance at 11.73ppm, thus confirming spin-coupling between these two 
resonances. From the temperature variation studies the resonance at 
5.41 ppm was identified as the a -:CH proton s 4, thus identifying the peak at 
11. 73ppm as . ?eing the secondary amide NH proton a4. The spin-coupling 
between these two protons in free vancomycin is zero hence spin-decoupling 
has no effect; a conformational change would therefore be necessary in 
order to observe an effect upon spin-decoupling of these protons in the 
complex. The large downfield shift for a4 of 3. 73ppm must be due to 
hydrogen bond formation upon complexation, the analogous proton in the 
ristocetin A complex undergoes a similarly large downfield shift of 
4.67ppm. 
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A CPK model of vancomycin incorporating a modified binding site73 
was built, based on the above data and being guided by reference to the 
ristocetin A binding site. The proton a4 can only be brought from the side 
of the molecule (as in the x-ray model) into the proximity of the 
carboxylate anion of the peptide, and hence a hydrogen bonding position, by 
means of a conformational change involving the p -hydroxy-chlorotyrosine 
unit of which it is a part, the iso-asparagine unit and the N-
methylleucine residue. The proposed changes are described below and can 
best be appreciated by reference to figures 6.7 and 6.8. 
(1) The a CH-CO bond of the N-terminal N-methylleucine unit is rotated 
(2) 
through --180°; from a position where the a.C- Hcc bond of this 
residue is nearly eclipsed with the N- H84 bond of the neighbouring 
p -hydroxy-chlorotyrosine unit ( figure 6. 7) to one where this 
a C-Hcc bond is approximately eclipsed with the carbonyl bond of 
the N-methylleucine (figure 6.8). 
The - CHY (OH )- CHs 4NH - bond of the 'right-hand' p -hydroxy-
chlorotyrosine unit is rotated as indicated in (6.1) until the 
conformation (6.2) is attained. This change brings the amide proton 
a 4 of the p -hydroxy-chlorotyrosine unit very close to proton a of 
ring 3, 
( 3) The rigid CONH unit, connecting the carbonyl of the above p-
hydroxy-chlorotyrosine unit to the amide proton a5 of iso-
asparagine, is rotated about the two bonds connecting it to its a-
carbons. This rotation, viewed from the iso-asparagine methylene 
group, is in a clockwise direction through -120°; during the 
rotation of the CONH unit, its amide proton a5 traverses the face of 
the ch~orine-bearing aromatic ring, its final position being on the 
same face as the chlorine atom. 
(4) The iso-asparagine methylene group is rotated, viewed in the 
-cH2..,.co- direction, anticlockwise by __.90°. As a consequence the 
methylene group, which is initially disposed relative to the 
carbonyl as in (6.3), is finally oriented as in (6.4). 
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The proximity of the peptide carboxylate anion to the cationic N-
methyl group, and the amide protons a4, a5 and a 3 is shown in figure 6.9. 
Further evidence in support of these modifications to form a carboxylate 
anion receptor pocket is now presented. Experiments with peptide analogues 
were performed using excusi vely 400MHz proton nmr in the slow exchange 
regime unless otherwise stated . A typical spectrum and expansions of 
vancomycin alone and complexed to Ac-D-ala-D-ala at o0 c are shown in 
figures 6.10-6.14. The bound and free positions of the dipeptide protons 
were confirmed by double irradiation and transfer of saturation studies on 
vancomycin in the presence of excess peptide. The full assignment of the 
vancomycin/ Ac-D-ala-D-ala spectrum is listed in table 6.5. 
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Table 6.5 Vancomycin/Ac-D-ala-D-ala ( 1 : 2) Assignment 
5ppm Assignment 5ppm Assignment 
0.51 ala 1Meb 5.40 t 
0.69 ii/ jj 5.47 S4 
0.93 ala2Meb 5.76 A2 
1. 02 gg 5.86 S3 
1. 18 ala 2Mef 5.98 A3 
1. 26 ff 6.20 r 
1. 28 ala 1Mef 6.31 1 
1. 38 j 6.69 a6 
1. 69 h/h 6.73 n 
1. 85 al a-Ac-Me 6. 81 k 
' 2. 14 0 6. 92 d 
2. 60 0 7. 17 a 
2. 65 hh 7.28 b 
3. 14-3. 66 sugar protons 7. 32 g 
3, 86 al a 1 CHb 7.46 C 
4. 16 cc/al a 1cHf 7,63 i 
4,30 ala2cHf 7,75 f 
4. 41 S1 8.02 ala2NHb+f 
4.50 S6 8. 10 ala 1NHf 
4. 61 s 2/x 8.37 a5 
4.68 ala2CHb 8.75 a1 
4, 74 S5 8.79 a2 
5. 13 z 9.00 a3 
5. 19 y 9.05 b2 
5. 22 v/m/bb 9. 15 b3 
5.24 9.28 b1 
5.36 A 1 ( ?) 11 • 75 a4 
Data collected in dmso-d6/30%CC1 4 at o
0 c (400MHz), 
Subsc.ript b=bound, f=free. 
The spectrum of the slow-exchanging complex was complicated by the 
appearance of several exchangeable resonances, due to amino and sugar 
hydroxyl protons, in the 5.36-9,41 region. Justification for the assignment 
of resonances not identified from the variable temperature studies will be 
given in the following text. 
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The nuclear Over ha user effect proved invaluable in the 
identification of the ristocetin A binding site; it has proved similarly 
useful in this study of vancomycin (negative effects only were observed). 
The standard Bruker gated nOe pulse sequence [2] was used throughout. The 
nOe's present in vancomycin under the experimental conditions used for the 
binding studies are shown in table 6.6, and are found to be identical in 
many cases to those found in vancomycin in dmso-d6 at 70°c37, It therefore 
appears unlikely that a major change in conformation has occurred upon the 
addition of 30% carbon tetrachloride to the solution of vancomycin in 
dmso-d6. 
Table 6.6 Vancomycin nOe's (all negative) 
Resonance Irradiated 
S6 
S4 
S3 
y 
t 
d 
g 
a6 
a4 
a2!a3 
a1 
nOe ( % ) 
a(25), b(20), f(25), z(20) 
y(30), a(20) 
a 2 (50), t(18), v(20), k(9) 
a(14), S4(10) 
d ( 6) , S 3 ( 15) , V ( 7) , gg ( 18) , ii/ j j ( 1 7) 
i(25), a 3(10) 
c( 40), V ( 8) 
c(15), z(15), A/10) 
y(20), bb(10), ff(12) 
s 3(40), s 2 (15), v(15), s 6 (10), k(10) , d(7) 
s 6 (17), f(20), s 2 (30), b(8), z(14) 
Data collected in dmso-d6/30%CC14 solution at 5°c (400MHz). 
In certain cases the initial build up of the nOe was studied by 
varying the length of the irradiating pulse, thus obtaining data relating 
directly to protons in the immediate vicinity of the irradiated peak. As 
the length of the pulse is increased so spin diffusion throughout the 
molecule, especially through exchangeable nuclei, has a greater effect 
thus limiting the usefulness of the 'nOe' information. The main 
difficulties encountered in nOe experiments came from spin diffusion. 
Although this is not unexpected for a molecule the size of vancomycin, the 
[2] See Bruker Software Manual 
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problem was greatly amplified if the sample .had not been completely 
desiccated (over phosphorous pentoxide/sodium hydroxide), as evidenced by 
a large water peak (HOD) at around 3.3ppm. 
The nOe time dependence of the amide proton a4, in the 
vancomycin /Ac-D-ala-D-ala complex , is shown in figure 6.1S (a typical nOe 
difference spectrum, from which the data is derived, is shown in figure 
6.16). The protons to which the nOe builds up most rapidy, and must 
therefore be closest to the irradiated proton a4, are i, as, cc and m/bb. 
The effect observed to the latter pair of sugar anomeric protons is 
probably due to spin diffusion, as evidenced by the slower initial nOe 
build up and the fact that the curve continues to rise beyond the 
theoretical maximum nOe level of 100% with no sign of curtailment within 
the bounds of the experiment. On the basis of this data and the binding 
site proposed above the exchangeable but unidentified resonance (the only 
such resonance in this region of the spectrum) at 8.37ppm was tentatively 
assigned as the amide proton as· The apparently anomalous but large nOe to 
i can be explained only if the aromatic ring 3, to which it is bonded, is 
rotated through 180° to bring it to the 'front face' of the molecule. This 
postulate would also account for the nOe observed37, in both directions in 
aglucovancomycin and vancomycin, between protons a and y, which are 
seemingly on opposite faces of the molecule. The most plausible 
explanation to account for this ( the ring is too hindered to rotate 
freely) is that during the preparation of the crystals of GDP-I, used in 
the x-ray analysis, a retro-claisen type of rearrangement ( scheme 6.6) 
occurred in which the aGH--pCH bond of the ring 3 p -hydroxy-
chlorotyrosine unit was cleaved. This would allow reconnection of this 
bond with the chlorine atom either on the front face, as in GDP-I, or on 
the rear face, as in vancomycin. 
A similar nOe time dependence study was performed for the amide 
proton as (figures 6.17 and 6.18). Again considering the initial nOe build 
up, and despite considerable spin diffusion with the longer pulse 
durations it can be clearly seen that the nearest protons are a4, a 3, i, o 
and ss· This confirms that the resonance at 8. 37ppm is indeed the amide 
proton as, and is al so substantial evidence in support of the proposed 
modifications to the vancomycin binding site . Further nOe's are presented 
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Table 6.7 Vancomycin/Ac-D-ala-D-ala (rv1:2) nOe's and Tos* 
Resonance Irradiated nOe/TOS (%) 
* 
ala 1Meb 
ala 2Meb 
ala-Ac-Meb 
ala 1 CHf 
ala 2cHf 
ala2NHb 
ii/ jj 
gg 
ff 
h 
s, 
S2 
S3 
X 
d 
a 
b 
g 
C 
i 
r 
ala 1Mef(30), d(7), ala 1cHb(7) 
ala 2Mef(10), f(7) 
ala 2NHb(15) 
al a ,CHb ( 30 ) 
al a 2cHb ( 40 ) 
ala-Ac-Meb(20) 
j(15), ala2Meb(25) 
ff(8), x(10) 
gg(10) 
j (40) 
z(10) 
b( 12) 
t(10), a2 (30) 
C ( 10) 
o( 15) 
s 2 (30), z(10), f(10) 
f(8) 
S3(15) 
t(8) 
S5 (20) 
A3 ( 10) 
i(25) 
y(50) 
z( 10) 
c(30) 
g ( 50) , a6 ( 15) 
d(7), a4 (7) 
s 1(7) , b1 (10) 
b2 ( 30) , b 1 ( 7) 
r(30), 1(20) 
1(20), b3(20) 
b2 ( 30) , n ( 30) 
y(20) 
z(25), a6 (20), c(30) 
Transfer of saturation (TOS) indicated by effects between 
bound (b) and free (f) components. 
Data collected in dmso-d6/30%CC1 4 solution at s0 c (400MHz). 
All nOe's were negative. 
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The position of the amide proton a3 was confirmed by the observation 
of an nOe to the somewhat isolated aromatic proton t , to which few nOe' s 
were observed. Other important effects observed were between the bound 
ala 1Me and the aromatic proton d (also reported in the . study of the 
analogous ristocetin A complex) and a large effect between proton a and 
proton y. The remaining nOe' s provide confirmation of many spectral 
assignments that have already been mentioned. 
Re-interpretation of the data presented by Convert and co-workers 66 
further supports the proposed carboxylate anion receptor pocket. They 
noted a marked change in the chemical shifts of the iso-asparagine 
methylene protons upon complex formation; in addition a large perturbation 
( > +25Hz) of the iso-asparagine amide proton a5 was reported. Both of 
these effects have also been noted in this study, although of increased 
magnitude. In view of the downfield shift of the amide proton a 3 upon 
complex formation (due to hydrogen bonding), it was concluded that the 
perturbation of a5 could not be due to hydrogen bond formation since the 
x-ray structure shows a 3 and a5 to be on opposite faces of the molecule. 
Further, seemingly anomalous shifts of protons d and i (also considered 
from the x-ray study to be on the rear face) were observed. In the light of 
the proposed conformational change and the structural modification 
involving rotation of ring 3 by 180°, it can be seen that the data are 
consistent with the hydrogen bonding of both a3 and a5 (in addition to a4 ) 
to the carboxylate anion; the protons d and i now being on the front face 
are proximal to the peptide binding site whioh would account for their 
observed shifts (the large shift observed for proton a is still reasonable 
in view of the fact that it is adjacent to the portion of the molecule 
undergoing the most major changes in conformation); and the methylene 
protons of the iso-asparagine residue do move considerably relative to a3 
in accord with their change in chemical shift. 
6.1.3 VANCOMYCIN/AC2-L-LYS-D-ALA-D-ALA BINDING STUDIES 
The dipeptide Ac-D-ala-D-ala, although providing information on the 
conformation of the right-hand portion of vancomycin upon binding [3] 
[3 J See Section 6. 1.2 
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still leaves unidentified possible interactions . which may occur between 
the antibiotic and the bacterial cell wall. The data of Nieto and 
Perkins 63 indicates that the vancomycin carboxylate anion is involved in 
binding, as deduced from the association constant increase of 100 for the 
Ac2-L-lys-D-ala-D-ala complex compared with the Ac-D-ala-D-ala complex. 
Interaction with the carboxylate group is presumed since ristocetin A, 
which has a methyl ester in the .position of the vancomycin carboxylate 
group, has an association constant increase of just 10 for the similar 
peptide complexes. From studies of CPK models it can be seen that the lys-
a -NH could interact with the car box ylate anion which would enable the 
flexible sidechain lys- e: -amino group to interact with the sugar moieties. 
Convert and co-workers 66 noted a large shift for the vancomycin amino 
sugar methyl group ff with Ac2-L-lys-D-ala-D-ala compared with Ac-D-ala-
D-ala. 
Preliminary experiments only have so far been performed producing 
disappointingly few results relating to the interactions of Ac2-L-lys, the 
third amino acid residue, with the antibiotic. This has mainly been due to 
considerable spin diffusion which has made spectral interpretation 
somewhat complicated, but additionally the appearance of seemingly 
anomalous resonances has hampered the full assignment of the spectrum. It 
has previously been noted that during experiments the decomosition of the 
Ac2-L-lys-D-ala-D-ala produces extra peptide signals. The partial 
assignment of the spectrum of vancomycin complexed to Ac2-L-lys-D-ala-D-
ala is shown in table 6.8. The assignments have been based on the previous 
study with Ac-D-ala-D-ala [4] and nOe and transfer of saturation data, 
which is presented in table 6.9. 
[4] See table 6.5 
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Table 6.8 Vancomycin/Ac2-L-lys-D-ala-D-ala (--1:2) Assignment 
oppm Assignment Oppm Assignment 
o. 52 ala 1Meb 5. 18 v/y 
0.68 ii/ jj 5.22-5.24 m/bb 
O. 93 ala2Meb 5. 41 t 
1. 03 gg 5. 50 S4 
1. 22 ala2Mef 5. 74 A2 
1. 27 ff/ala 1Mer/lysYCH2r 5.82 S3 
1. 38 lys6 CH 2f 5.97 A3 
1. 44 j 6.25 r 
1. 55 lys pcH 2r 6.36 1 
1. 78 lys t AcMef 6.63 a6 
1. 84 lys t AcMeb/lysa AcMef 6.68 n 
2. 00 lysa AcMeb 6.76 k 
2. 16 0 6.91 d 
2. 57 hh 7.03 b 
3.00 lys t CH 2r 7. 15 a 
3.09 sugar proton 7.28 g 
3. 18 lys t CH 2b 7.43 C 
3. 28-3. 63 sugar protons 7. 65 i/ala2NHf 3.88 ala 1CHb 7,76 f 
3. 98 ala ,CHr 7.84 lys t NHb 
4. 17 cc(?) 7. 96 lys £NHf 
4.21 lysa CHr 8.06 lysa NHf 
4.36 ala2CHr 8. 13 lysa NHb 
4. 41 s 1/lysa CHb 8. 18 ala 1NHr 4,63 ala2CHb 8.37 a5 
4. 67 x/s2 8.75 a2 
4. 71 S5 9.03 a3 
4. 96 S6 9.48 a1 
5. 13 z 11. 62 a4 
Data recorded in dmso-d6/30%CC14 at 10°c (400MHz). 
All nOe's are negative. Subscript b=bound, f=free. 
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Table 6.9 Vancomycin/Ac~-L-lys-D-ala-D-ala (,,_..1:2) 
nOe's and TOS 
Resonance Irradiated 
gg 
ala2Mef 
lysOCH2r 
lys pcH 2r 
lysa AcMeb 
0 
lysECH2r 
lys ECH 2b 
ala 1cH,b 
s 1 /lysaCHb 
v/y/z/m/bb 
t 
n0e/T0S (%) 
ala 1MerC20), ala 1cHb(12), gg(8), d(7) 
ii/jj(30), ala2Mer(15), gg(12), 
x/s2 (7), f(7) 
ala 2Meb(15), ala2Mer(20), ala2CHb(10), 
ff/ala 1MerllysYcH2rC15) 
ala2Meb ( 12) 
lys e: cH2r< 1 o) 
ff /ala 1Mer/lysYCH 2r(20), ala2Mef( 15) 
lysaAcMer/lys £AcMeb(30) 
s 5 (15), lysaAcMeb(15), ii/jj(10) 
lysOCH2rC10), lys £NHr(5) 
lys e: CH 2rC15), ff/ala 1Mer/lysYCH 2rC8), z(8) 
ff/ ala 1Mer/ ala 2Mer!lysYCH 2rC 16), 
ala 1CHr(20), ala 1Meb(15) 
ala 1CHb(30), v/y/m/bb(10) 
lysa CHb/s 1(25), ala2CHb(10), v/y(10), 
ala2Mer(10), x/s2!s5 (12) 
ala2CHb(35), lysOCH 2rC9), 
ff/ala 2Mer/ala 1Mer/lysYCH 2rC12) 
lysOCH 2rC20), ala2Mer< 15), lysa CHrC 15), 
ala2CHb(15), s 5 (14), v/y/m/bb(15), 
lysa NHb ( 15) 
ff/ala 1Mer/lysy cH2rC18), gg(14), 
ala2CHr< 17) 
ala2CHrls 1/lysaCHb(20), f(12), 
v/y(15), ff/ala 1Mer/lys ycH2rC12) 
v/y/z(60), ala2cHb/x/s2;s5(25), f(10), 
s 1/lysa CHb(12), b(8), lysaAcMeb(7) 
a( 12) 
v/y(40), s 5;s2/x/ala2cHb(15), 
ff/ala 1Mer/lys yCH2rC10) 
v/y(60), ala2M~r(20) 
v/y(50), a2 (20) 
1(30), v/y/m/bb(12) 
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Table 6.9 Continued 
Resonance Irradiated 
b 
a 
g 
C 
i/f 
f / i/lys t NHb 
nOe/TOS (%) 
k(40), v/y/m/bb(12), c(10) 
n/a6 (40), v/y(10) 
z/v/y/m/bb(25), i/ala2NHf(12), 
ala 1Meb(15), ala2CHb/x/s2!s5 (12) 
ff/a~a 1Mef/lys yCH 2f(10) 
z/v/y/m/bb(30), ala2cHb/x/s2!s5 (20), 
ala 1Mef/ff/ala2Mef/lys yCH 2f(10), 
ala2cHf/s 1/lysa CHb(10), s 6(10) 
z/y/v/m/bb(40), g(15) 
c(25), z/v/y/m/bb(22), a(9) 
g(35), ala2Mef(13), a6 (12) 
z/v/y/m/bb(30) 
z/v/y/m/bb(17), d(15) 
ala 2CHb/x/s2!s5 (25), z/v/y/m/bb(25), 
ala 1Mef/ala2Mef/ff/lysyCH 2f(12), 
ala2Meb ( 12) 
lys t NHf(18), ala2cHb/s2!s5/x(17), 
z/v/y/m/bb(16) 
v/y/z/m/bb(25), lys t AcMeb/lys aAcMef(15), 
ala 1Mef/ff/ala2Mef/lys yCH 2f(10) 
ly~ t NHb(25), lys t CH2f(20) 
v/y/m/bb(15), lys aAcMef/lys t AcMeb(10), 
ala2Mef/ala 1Mef/ff/lysyCH 2f(15), 
s 1/lysa CHb(12), ala2CHb/s2!s5/x(11) 
lys~cH2f(14), s 1/lysa CHb(14), 
v/~/m/bb(12), ala2Mef(13) 
s 5 (15), v/y/m/bb(30), a 3(14), 
a4 (8), ii/jj(9) 
s 3 (30), v/y(30), ala2cHb/s2!s5/x(12), k(8) 
v/y/m/bb(30), ala2cHb/x/s2ls5 (30), 
t(20), a5 (5) 
f(30), ala2cHb(10), z/y/v/m/bb(35), 
ala2Mer(15) 
a5 (30), i(20),' a 3 (8), z/v/y/m/bb(30), 
ala2Mef(20) 
Data recorded in dmso-d6 /30%CC1 4 at 10°c (400MHz). 
* Transfer ~f saturation (TOS) indicated by effects between 
bound (b) and free (f) components . 
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Compared to the vancomycin complex with Ac-D-ala-D-ala three 
resonances were found to be significantly (>o. 1ppm) affected by the 
addition of a third residue to the bacterial cell wall analogue . They were 
s 6 ( despite spin diffusion confirmatory nOe' s to z, s 2, f and b can 
reasonably be identified) which was deshielded by 0.46ppm; b was shielded 
by 0. 25ppm ( confirmatory nOe' s to z, s 6 and s 2 ); a 1 was deshielded by 
0.73ppm (confirmatory nOe's to f, z and ala2CHb). From CPK model building 
studies the deshielding of a 1 and s 6 is due to the proximity of the 
lysylaAc-CO or a conformational change of the antibiotic carboxyl group 
induced upon the addition of tripeptide, or is perhaps a combination of 
the two effects. The shielding of aromatic proton b would occur if the 
aliphatic lysyl sidechain was oriented towards the sugar moieties. 
Despite the effects of spin diffusion a similar pattern of nOe's was 
observed for the right-hand portion of the antibiotic . Notably the nOe 
previously observed with Ac-D-ala-D-ala from the ala 1Me group to the 
vancomycin proton d was al so observed, and in both directions, with 
tripeptide . Transfer of saturation identified many of the peptide 
resonances except for three of the four bound lysyl methylene group 
protons which remained unidentified and may account for some of the 
effects observed in the methyl region. 
Possible effects with the lysyl residue involved the lys £CH 2b (z and ff), lysaCHb (ala2CHb and b), lys a AcMeb (s6 ) and lys£ NHb (z/m/bb). Since 
all of the perturbed nuclei were on or around the triaryl unit of 
vancomycin with no effects observed to nuclei on the biphenyl unit the 
obvious conclusion is that the lysyl sidechain is oriented towards z or 
the sugars, or is flexible and can occupy one of several positions in this 
region of the antibiotic. The lysNH protons were not significantly shifted 
upon binding, hydrogen bonding is therefore not confirmed to either of 
them al though it probably occurs from the a -NH to the carboxyl of 
vancomycin, as evidenced by the deshielding of a.1 noted above. 
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6.1.4 CRISTAU.ISATION STUDIES 
The most conclusive manner in which to identify a binding site is by 
an x-ray study of the complex. Since the vancomycin derivative CDP-I could 
be readily prepared in a crystalline form it was feasible that if a 
bacterial cell wall analogue was present in solution, then under the same 
conditions crystals of CDP-I bound to the analogue may be obtained. 
Crystals of CDP-I were obtained by heating (8o 0 c, 2 days) aqueous 
solutions ( pH 3, 4 or 4.2) of vancomycin. Dark brown, irregular shaped 
crystals were produced at both pH's, al though superior crystals were 
obtained at pH4.2, An equimolar (50mM) solution of vancomycin and Ac-D-
ala-D-ala was prepared. It was found to be more acid (pH2.4) than a 
solution of vancomycin alone and a precipitate formed above pH 3. 
Incubation for 16 hours at 80°C produced a gel only. A similar result was 
obtained with a 20mM solution. This result is perhaps not surprising in 
the light of the contention74 that CDP-I does not bind to bacterial cell 
wall analogues. 
Further studies were performed which involved diffusing a volatile 
precipitant onto the surface of the sample thereby slowly reducing the 
solubility of the components at the interface. Experiments were performed 
on vancomycin alone, an x-ray analysis of which could confirm the proposed 
rotation of ring 3, and with one equivalent of Ac-D-ala-D-ala present in 
solution with the antibiotic. Unfortunately none of the systems produced 
crystalline residues [ 5 J • 
6. 1.5 EPILOGUE 
So far no evidence has been considered with respect to whether 
vancomycin in solution, and in the absence of bacterial cell wall 
analogues, adopts to any extent one particular conformation in preference 
to any other. Vancomycin alone in dmso-d6 solution does appear to adopt 
the conformer found in the crystal; no evidence has been found to support 
the existence of the alternative conformation . [ 6 J formed upon 
[5] See Chapter 8 for experimental details 
[6] Pr oposed i n Section 6.1.2 
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complexation. Data in support of this last statement can be found by 
comparing the data in figure 6.15 [7] with those presented in table 6.6 [8] 
• In the latter case only do protons y and a4 experience an nOe to and from 
one another and in addition proton s 4 exhibits an nOe to proton a5 37, These 
effects would only be observed if the conformation of vancomycin in 
solution was similar to that deduced from the crystal study. 
The proposed carboxylate anion receptor pocket (figure 6.8) bears a 
remarkable resemblance to that found in ristocetin A67. However, the 
receptor pocket of ristocetin A for the carboxylate anion is 
conformationally rigid whereas that for vancomycin is formed on demand 
from a conformationally mobile part of the molecule . Thus, in the 
dissociation of the vancomycin/Ac-D-ala-D-ala complex, numerous 
additional rotors will become available. This extra loss of order which 
can occur upon dissociation of the complex may well account for, at least 
in part, the smaller free energy of activation ( f1 G=55KJ.mole- 1, Tc=16°c, 
Ov=308Hz) for dissociation relative to the value ( f1 G=75KJ.mole- 1 ) found 
for the ristocetin A/Ac-D-ala-D-ala complex. 
6.2 RISTOCETIN A - CRYSTALLISATION STUDIES 
The structure of ristocetin A, based on chemical and nmr studies, has 
recently been proposed 51 . Although the data appears unequivocal , 
confirmation by an x-ray crystal study is desirable. 
At first glance through the literature this task does not seem too 
daunting since one of the early papers on ristocetin 74 describes the 
routine preparation of ristocetin crystals from an aqueous ethanolic 
solution. The experiments involved dissolv~ng ristocetin (commercially 
available as the hydrogen sulphate) in four parts of water, eight parts of 
95% ethanol solution was . then added and the solution warmed. 
[7] The nOe's of a4 in the complex [8] The nOe's of free vancomycin 
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Crystallisation proceeded over a period of several days. A photograph of 
the crystals and x-ray diffraction data · was presented. Repeating this 
experiment was an obvious starting point for the present studies, but 
although it was attempted several times no success was enjoyed and other 
techniques and solvent systems were therefore evaluated. 
Crystallisations are generally effected by dissolving the sample (a 
few milligrams) in a suitable solvent and then reducing its solubility by 
the addition of a second solvent, almost to the point at which 
precipitation would occur. Crystals often form if this process progresses 
slowly enough. Small molecules ( for example some of the protected amino 
acids described in Section 6.1.1) often crystallise by simply shaking in 
such two solvent systems. However, for a molecule as complex as ristocetin 
more refined techniques are required. The two methods which have been most 
extensively used in these studies are vapour diffusion, in which a 
volatile precipitant diffuses onto the surface of the sample solution 
thereby reducing the solubility until crystallisation (or precipitation) 
occurs; and the layering method, in which the precipitant is carefully 
layered on top of the sample solution. The latter method was found to be 
more vigorous than the former, often producing precipitation when crystals 
were obtained in the analogous vapour diffusion experiment. Many solvent 
systems were evaluated and several of them produced crystalline residues, 
although only a water/75% acetone system was found to produce crystals of 
suitable quality for x-ray analysis. This system was also used to increase 
the purity of the antibiotic which then produced a larger number of single 
crystals in preference to multiple crystals. The crystals, al though of 
exceptional quality, were found to be unstable upon x-ray bombardment for 
more than 3-4 hours, which was insufficient for the collection of a full 
data set. 
Ristocetin A is supplied as the hydrogen sulphate salt, since this 
does not produce crystals suitable for analysis it was suggested75 that 
conversion to another salt, for example the iodide, may generate crystals 
of a different form which might be more stable towards x-rays. The iodide 
salt was prepared by reaction of an aqueous solution of ristocetin A with 
an aqueous solution of barium iodide, the supernatant of ristocetin A 
iodide salt was separated from the precipitate of barium sulphate by 
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centrifugation. Freeze drying was used to concentrate and dry the sample. 
Several solvent systems were tried but none produced a crystalline 
product. 
The technique of salting-out, which has been successfully employed 
for oligopeptides and proteins, was also tried but produced crystals of a 
needle-like form which were not suitable for x-ray analysis. 
The derivative \JJ -aglycone of ristocetin was al so used for 
crystallisation studies since, if successful, it would greatly simplify 
interpretation of the data both because the molecular weight was 
significantly reduced and because the mobile tetrasaccharide unit (which 
may obscure details of the aglycone moiety) had been removed. Crystalline 
residues were not obtained from any of the solvent systems tried. 
Confirmation of the binding site of ristocetin A was sought using 
both Ac-D-ala-D-ala and Ac2-L-lys-D-ala-D-ala. Crystals of both comlexes 
with ristocetin A were obtained from the water/75% acetone system although 
only the dipeptide formed a stable complex. The crystals of ristocetin A 
and Ac-D-ala-D-ala were cubic in nature, having a unit cell of ,_,140,000i3 
and was comprised of trimer sub-units, of which there were 24 per unit 
cell. Unfortunately there are no methods currently available which could 
be used to analyse such a crystal to the desired resolution. 
6.3 TRIOSTIN A 
It has previously been reported53 that in deuteriochloroform 
triostin A exists in two symmetrical conformations separated by an energy 
barrier of 92KJ.mole- 1. One conformer is favoured in polar solvents, the 
other in non-polar solvents. The postulated difference between them, apart 
from minor movements about the cyclic peptide backbone, is the chirality 
of the disulphide cross-bridge. This conclusion was based on nmr chemical 
shifts , coupling constants , temperature and solvent shifts, and lanthanide 
induced shifts (LIS)54. Direct evidence , largel y depe ndent upon nOe ' s, is 
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now presented which more precisely describes the conformers. 
The 400MHz 1H nmr spectrum in deuteriochloroform (figures 6.19-6.22) 
was assigned using double irradiation techniques, with reference to the 
assignments previously made at 270MHz53. The existence of significant 
proportions of each conformer produced complex spectra, from the overlap 
of resonances and transfer of saturation upon the execution of nOe 
experiments. Both positive and negative nOe's were observed in 
deuteriochloroform solution at 30°c and all were below 2% in magnitude. It 
therefore seemed that these conditions were on the threshold for changing 
the sign of the nOe ( the position of minimum nOe). An increase in 
temperature would have been expected to produce larger and more positive 
enhancements whereas a decrease in temperature would have favoured 
negative effects. However, the small temperature variations that one could 
reasonably achieve with the nmr machine were insufficient to 
significantly influence the equilibrium existing between the two 
conformers. It was desirable to manipulate the equilibrium such that one 
conformer was greatly favoured over the other in order that spectral 
simplification could be accomplished. 
Solutions containing solely triostin-p could readily be obtained by 
adding 25% dmso-d6 to a solution in deuteriochloroform, however the n-
conformer was more of a problem. In addition to polarity and solubiltiy 
problems a solvent was required which would produce larger nOe's, 
preferably negative, than those observed in deuteriochloroform at 30°c. In 
order to attain this last objective increasing the solvent viscosity or 
decreasing the temperature would be necessary. In view of the added 
consideration of changing the equilibrium of the conformers in favour of 
triostin-n the former was most desirable. The recent work of Williamson 
and Williams7 6 has shown that the oil Vol talef 1 OS has great application 
for the manipulation of the nOe. It is very viscous ( 1550cp at 25°c) 
compared to other common solvents such as chloroform (0.54cp) and dmso-
d6 (1.98cp) and since it is a polymer of chloro-trifluoroethylene it has no 
protons to interfere in the spectrum. It is not in itself a good solvent 
but it is miscible with most organic solvents thus enabling solutions of 
many reasonably non-polar molecules to be obtained. 
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Triostin A was dissolved in deuteriochloroform and Voltalef 10S was 
then added; a 1: 1 solution was the highest oil concentration possible 
without precipitation of the antibiotic. Unfortunately at 30°c the 
equilibrium was only slightly moved in favour of triostin-n (rv 2: 1), but an 
nOe series produced some very interesting results. Irradiation of then-
cys- a -CH produced a 16% negative effect to the n-val- a -CH and 
essentially little else (figure 6.23), this was supported by an 18% 
negative effect in the reverse direction (figure 6.24). In order to check 
whether this enhancement was unique to triostin-n the p-cys- a -CH 
resonance was irradiated; a 19% negative nOe was observed to one of the N-
methyl groups only (figure 6.25). The previous studies [9] have shown that 
echinomycin and triostin-p have similar conformations . The cys- a -CH and 
the val-N-Me are known to be on the upper, quinoxaline-ring bearing face 
of the antibiotic disc whereas the cys-N-Me is on the lower face. From 
examination of a CPK model of triostin-p it can be readily appreciated 
that the cys- a -CH and val-N-Me are potentially close enough to touch one 
another whereas no sizeable interaction is feasible with the cys-N-Me. The 
enhanced N-Me was therefore assigned to the valine residue. A 12% nOe from 
the p-cys-N-Me to p-ala-CH further supports this model. In addition a 7% 
nOe from the p-cys-N-Me to p-val- p -CH indicates that the bulky val ine 
side-chain is oriented towards the lower face, away from the binding site. 
A 5% nOe from the p-cys- p2 -CH to p-cys-N-Me, with no effect observed 
between the p-cys- a -CH and the p-cys- p -CH protons, suggests that the p-
cys methylenes are on the lower face. From CPK model building the 
disulphide bond can readily move from the lower to the upper face with 
.little distortion to the rest of the molecule and so cannot be assigned to 
either face with certainty, indeed it may be that in solution it freely 
interconverts between the two . The observed nOe's are presented in tables 
6. 7 and 6. 8. · 
[9] See Section 2.3 
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Table 6. 10 Triostin-n nOe's (all negative) 
Resonance Irradiated 
cys- a CH 
cys-N-Me/cys- p 1cH 
cys- p 2cH 
val- a CH 
val- p CH 
val-N-Me 
val- y Me' S 
ala-Me 
ala-NH 
ala-CH/ser- a CH 
ser- p 1 CH 
nOe (%) 
val- a CH(16), cys- p 2cH(2) , cys- p 1cH(2), 
cys-N-Me(3) 
cys- p 2cH (40), ala-CH (4), cys - a CH (3) 
val- a CH(3), val-N-Me(3) 
val- a CH(4), cys- a CH(4), val-N-Me(2) 
cys- a CH(18), val- y Me's(3), val- ~ CH(3), 
cys- p1cH(4), cys-N-Me(3), ser- p 1cH(2) 
val-N-Me(5), val- y Me's(4), val- a CH(1) 
val- ~ CH(10), val- y 1Me(4), cys-N-Me(5) 
val- ~ CH(6), ala-Me(4), val- a CH(3), 
val-N-Me(3) 
ala-NH(6), ser- a CH/ala-CH(7), 
val- y Me's(3), ser-NH(3), cys-N-Me(1) 
ser-NH (7), ser- a CH/ al a-CH (7), 
ala-Me(5), cys-N-Me(3), ser- p 2cH(3) 
cys-N-Me (8), ser- p 1 CH (3), ser- p 2 cH (2), 
ala-Me(2), ala-NH(2), ser-NH(2) 
ser- p 2cH(29), val- a CH(5), ser- a CH(5), 
ala-NH(3), cys-N-Me(2) 
ser- p 1 CH ( 40) , ser- a CH/ al a-CH ( 1 0) , 
ala-NH(5), ser-NH(4), cys-N-Me(2) 
Data recorded in coc1 31vo1talef 10S (1:1) at 30°c (400MHz) . 
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Table 6. 11 Triostin-p nOe's (all negative) 
Resonance Irradiated 
cys- a CH 
cys- p 2cH 
cys-N-Me 
val- a CH 
val- p CH 
val- y 2Me 
val- y 1Me 
ala-Me 
ala-CH 
ala-NH 
ser- a CH 
ser- p 1 CH 
ser- P 2cH 
ser-NH 
nOe' s ( % ) 
val-N-Me(19) 
val-N-Me/cys- p 1CH(8), cys-N-Me(5) 
ala-CH(12), val- p CH(7), ala-Me(7) 
val- y 2Me(5) 
val- Y 2Me(4), val-N-Me(2) 
val-PCH(6), val- y 1Me(4), val- a CH(3) 
val- p CH(3), val- a CH(2) 
ala-CH(2), val-N-Me(1) 
cys-N-Me(7), ala-Me(3) 
ser- a CH(5), val-N-Me(2), ala-Me(3) 
ser- p 2cH(15), ser- p 1cH(7), val- a CH(3) 
ser- p 2cH (50), ser- a CH ( 12) 
ser- p 1CH(15), ser- a CH(4) 
ser- a CH (4) 
Data recorded in coc131vo1talef 10S (.-..1:1) at 30°c (400MHz) 
The data was by no means unambiguous as far as the interpretation 
was concerned; considerable problems were encountered from transfer of 
saturation and overlapping resonances, as in neat deuteriochloroform 
solution. However, the effects observed between the n-cys- a -CH and the n-
val- a -CH were so large, relative to any other nOe involving either of 
these protons, that they obviously provide the main dipolar relaxation 
mechanism for each other. In order for this to be realised they would need 
to be very close in space and without any other proton in the immediate 
vicinity. 
The cys- a -CH is rigidly held at the intersection of the cross-
bridge with the peptide backbone and therefore cannot be significantly 
moved. The p-val- a -CH must therefore be moved towards the cys- a -CH. 
Rotation of the cys-val amide bond is necessary and can involve moving the 
N-Methyl group inwards towards the centre of the disc, or outwards. Both 
options necessarily involve the trans configuration being modified either 
partially or completely towards the cis amide bond. The val- a -CH and cys-
a-CH can be moved together by moving the N-Me group inwards such 
that et> is reduced from 180° to ,.._,130°, further movement is not possible 
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because of steric crowding. However, the anticipated nOe between the n-
val-N-Me and the n-ala-NH, which have been moved very close together, is 
not observed, and the arrangement is also somewhat strained. In addition 
the lanthanide induced shifts cannot be reconciled with the structure 
attained. 
The more likely change involves rotation of the val- a -CH inwards 
towards the cys- a -CH. The val-N-Me is necessarily moved to cis with 
respect to the cys-CO to allow the close approach of the two a -CH 
protons. The cys- ~ -CH protons are moved close to the cys- a -CH and the 
val- a -CH protons since the only nOe's involving the cys- ~ -CH's are with 
these two a -CH protons. These few changes also have the effect of moving 
peptide residues on opposite sides of the ring together, above the disc. 
Notably the two alanine residues are now opposite one another, the NH of 
one being proximal to the carbonyl of the other. It is therefore apparent 
that hydrogen bonding of the ala-NH, previously proposed to be with the 
quinoxaline carbonyl, is actually across the ring to the other ala 
residue's carbonyl function. Hydrogen bonding across the ring is known to 
occur in tandem26, but is between the ala-CO and the val-NH. Obviously N-
methylation of the valine residue prevents an analogous interaction in 
triostin-n. Further minor changes of conformation may be involved but no 
other major changes. It is noticeable that the molecule is converted from 
an open conformation to a globular arrangement, which would also account 
for the larger number of nOe's observed in triostin-n compared to 
triostin-p. 
In order to obtain further nOe' s, and increase the effects already 
observed, spectra were recorded in CDc131vo1 talef 10S at -1 o0 c ( table 
6.12). This also had the effect of moving the equilibrium in favour of the 
n-conformer ( ,_,, O: 1). 
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Table 6.12 Triostin-n nOe's (all negative} 
Resonance Irradiated 
cys- a CH 
cys- p 1CH/cys-N-Me 
val- a CH 
val- p CH 
val- y 1Me 
val- y 2Me 
val-N-Me 
ala-CH 
ala-Me 
ala-NH 
ser- a CH 
ser- p 1cH 
nOe (%) 
val- a CH (73), cys- p 2cH (43), val-N-Me(7), 
cys- p 1CH/cys-N-Me(41), val- y Me's(12) 
cys- p2CH(67), cys-aCH(21), val-aCH(19), 
val-N-Me( 11) 
cys- a CH (55), cys- p 1 CH/ cys-N-Me (29), 
cys- p 2CH(20), val- YMe's(19), 
val- p CH(15), val-N-Me(11) 
val-N-Me(43), val- y Me' s(40), val- a CH (5), 
cys-N-Me(4) 
val- y 2Me(17), val-N-Me(14), val- P CH(10), 
cys-N-Me(7), val- a CH(5) 
val.:. y 1Me(15) , val- p CH(9), val-N-Me(4), 
cys-N-Me(4), val- a CH(4) 
val- p cH(8), cys-N-Me(3) 
cys-N-Me(49), ala-Me(20), ala-NH(9) 
ala-CH(13), ala-NH(9), cys-N-Me(8), 
ser-NH(5) 
ala-CH/ser- a CH(29), ser-NH(27), 
ala-Me(20),cys-N-Me(10) 
ser- p 1CH(24), ser- p 2cH(20), cys-N-Me(13), 
ala-NH(11), ser-NH(10) 
ser- p 2CH(100), ser- a CH(62), ala-NH(23), 
ser-NH(18), cys-N-Me(9), val-N-Me(5) 
Data recorded in coc1 31vo1talef 10S (,_,1: 1) at -10°c (400MHz) 
A large increase in spin-diffusion was evident from the fact that 
several cumulative nOe's from indi victual protons exceeded 100%, the 
theoretical maximum nOe from any single nucleus. The previously proposed 
model was supported by an overall pattern of nOe's which was very similar 
to that in the same solvent system at 30°c, although the magnitude of _the 
observed effects was greater. The effects between cys-a -CH and the val-
a-CH were greatly incre~sed and were the largest nOe's observed between 
non-geminally coupled protons. The difference spectrum after irradiation 
of the n-val- p -CH proton ( figure 6.26) shows similarly large increases in 
the nOe's to the n-val-N-Me and to the n-val- y -methyls, confirming their 
assignment. The lack of any significant nOe to the n-val- a - CH proton 
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indicates that the n-val- p -cH is effectively masked from it by the n-val-
N-Me and the n-val- y -Methyl groups. No new nOe's were observed that were 
of diagnostic significance. 
The triostin-p nOe's, previously recorded in the presence of 
triostin-n, were ratified by recording spectra in dmso-d6 solution (table 
6. 13). 
Table 6.13 Triostin-p nOe's (negative unless otherwise stated) 
Resonance Irradiated 
cys- a CH 
cys-N-Me 
val- a CH 
val- p CH 
val- Y Me' s 
val-N-Me 
ala-Me 
ala-NH 
ser- p 1cH 
ser- a CH 
ser-NH 
nOe (%) 
val-N-Me(21), cys- p 2cH(5), cys- p 1CH(4), 
cys-N-Me ( 1 ) 
cys-[J 1CH(30), cys- aCH(8), cys-N-Me(8), 
ala-Me(8), val- Y Me' s( 12) 
ala-CH/ser- fJ 2CH(12), val- y Me' s(10), 
ala-Me(8), cys- fJ 2cH(4) ,cys- a CH(1) 
val- y Me's(5), ser-aCH(5), va1- p cH(2), 
ala-NH (2), ala-Me(2) 
v al- Y Me' s( 1 ) 
val- a CH(2), cys-N-Me(2) 
cys- a CH(20), val- YMe's(8), ala-Me(6), 
v al- p CH ( 6) , ser-NH (2) 
ala-CH(10), ala-NH(8), cys-N-Me(6), 
val- Y Me' s(2) 
ala-Me(5), val-YMe's(3), ala-CH(1), 
ser-NH(1), cys-N-Me(1) 
ser-/J 1CH(15), cys-N-Me(8), ser- aCH(7), 
ala-Me(2), ala-NH(1) 
ser- p 2cH/ala-CH (28), val-Y Me' s( 11), 
ser- a CH(10), cys-N-Me(5), ala-Me(3) 
ser-NH (3), ser- /J 1 CH (3) , val- a CH (3) , 
ser- p 2CH/ al a-CH ( 3) 
val- y Me' s(20), ser- /J 2cH/ala-CH (6), 
ala-Me(13), ala-NH(6), ser- a cH(5), 
Q-H 3 (+4), cys-N-Me(3), ser- p 1cH (1) 
Data recorded in dmso-d6 at 19°c (400MHz) 
The spectrum of triostin-p was assigned by double irradiation 
techniques and with reference to the assignments previously made in 
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deuteriochloroform (figure 6.27). The difference spectrum obtained after 
double irradiation of the cys- p 2 -CH proton ( figure 6.28) identified the 
cys- p 1-CH proton in a position 0.67ppm highfield of its position in 
deuteriochloroform. Similarly, the ala-NH shifts 1.09ppm downfield in 
dmso-d6 solution. Both of these effects are obviously due to the effects 
of solvation and may be due solely to hydrogen bonding of solvent to the 
ala-NH, which apart from deshielding the amide proton could al so shield 
the cys- p 1-cH. The assignment of triostin in various solvents is 
presented in table 6. 14. 
Again the overall pattern of the nOe's of triostin-p in dmso-d6 
closely resembled that observed in deuteriochloroform solution. Spin 
diffusion was evident from the apparent nOe's between distant protons, for 
example between the cys-N-Me and the ser-NH. An enhancement between the 
cys- a -CH and the cys-methylene protons, not previously observed, 
indicates that these protons are proximal. In addition the nOe's between 
the cys- p 2 -CH and the cys-N-Me, and the absence of any other effects 
involving the cys-methylene protons wou l d indicate a cross-bridge 
orientation as in (6.5). 
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Table 6.14 Triostin A 1H Chemical Shift ( 6 ppm) Correlations 
Resonance Conformer CDc1 3 dmso-d6 CDC1 3/Vol talef 10s 
cys- a -CH n 5.66 5. 64 
cys- a -CH p 6.76 6. 19 
cys- (3 1-cH n 3.26 3.27 
cys- p 1-CH p 2.99 2. 32 
cys- p 2-CH n 3 . 35 3.39 
cys- p2-CH p 3.23 3. 64 
cys-N-Me n 3.25 3.27 
cys-N-Me p 2. 92 2. 88 
val- a -CH n 4.20 4. 19 
val- a -CH p 5. 16 4. 86 
val- P -cH n 2.28 2.24 
val- p-cH p 2.27 2.39 
val- y 1-Me n o. 97 o. 96 
val- y 1-Me p 0 . 80 o. 97 
val- y 2-Me n 1. 06 1. 04 
val- Y 2-Me p 1. 02 0 .99 
val-N-Me n 2. 97 2. 97 
val-N-Me p 3. 02 3.29 
ala-CH n 4. 97 4. 97 
ala-CH p 4.71 4.59 
ala-Me n 0. 61 0.62 
ala-Me p 1. 39 1. 31 
ala-NH n 8.32 8.38 
ala-NH p 7. 15 8.24 
ser- a -CH n 5.00 5.03 
ser- a -CH p 4.88 4. 95 
ser- p 1-CH n 4.52 4.54 
ser- p1-cH p 4.42 4 . 45 
ser- p2-CH n 4. 65 4. 64 
ser- P 2-CH p 4.54 4.59 
ser-NH n 8. 91 8.98 
ser-NH p 8.79 8 . 54 
Quinox .-H 3 n 9.53 9.56 
Quinox .-H 3 p 9. 60 9.56 
The CDC1 3 data was recorded at 30°c, 
the dmso-d6 data at 19°c and the 
CDC1 3 /Voltalef 10S (--1: 1) solution data at -10°c (400MHz). 
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7. CONCLUSIONS 
The studies described in this dissertation have been conveniently 
divided into three sections according to antibiotic. It is pertinent to 
retain this distinction in this summary. 
7. 1 VANCOMYCIN 
The binding of Ac-D-ala-D-ala to vancomycin has been studied in 
detail. The antibiotic undergoes a considerable conformational change 
around the right-hand (N-methylleucine, etc.) part of the molecule. Protons 
and the protonated N-methylleucine amino group form a 
carboxylate binding pocket which is very similar to that previously 
proposed for ristocetin A with the same dipeptide. The main achievement 
which enabled this detailed study to be performed was the attainment of 
slow exchange conditions by the use of mixed solvent systems in the nmr 
studies. 
A simple procedure was developed for the preparation of the 
tripeptide Ac2-L-lys-D-ala-D-ala involving reaction of the commercially 
available di-CBZ-L-lysine (activated as the succinimide ester) with the 
benzyl ester of the commercially available dipeptide D-alanyl-D-alanine. 
Hydrogenation and acetylation produced the required peptide. This peptide 
was then used_ for preliminary binding studies with vancomycin. The 400MHz 
spectrum of the complex was partially assigned and the protons a 1, s 6 and b 
identified as the only resonances which were significantly shifted 
(>O. 1ppm) by the presence of the third peptide residue. The few nOe' s 
involving bound lysyl protons indicated that the sidechain was oriented 
towards the triaryl unit of vancomycin. The large deshielding of a 1 can 
r easonably be accounted for by a hydrogen bond between the lysaNH and the . 
vancomycin carboxylate , al t hough the NH pr oton was not significantly 
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deshielded. 
One interesting observation derived from the mode of action studies 
was the fact that nOe's involving protons d and i of vancomycin with 
protons on the front face of the molecule and more importantly between d 
and ala 1Meb were contrary to the accepted structure of vancomycin. 
Rotation by 180° of ring 3 of vancomycin must be involved and this would 
al so account for the large, but previously unexplained, nOe between a and 
y. 
7.2 RISTOCETIN A 
Extensive crystallisation experiments were initiated with the aim 
of obtaining a confirmatory (or otherwise) x-ray analysis for the previous 
chemical and nmr studies of ristocetin A. Several systems were successful 
in producing crystalline residues but one in particular, water/75%acetone, 
was superior with regard to crystal quality. In addition the water/75% 
acetone system is the first method for the routine preparation of 
ristocetin A crystals. Unfortunately the crystals proved unstable under x-
ray bombardment but hopefully the ristocetin A purified by this method 
will be more amenable to crystallisation with other systems (possibly one 
of those already tried [1] with commercial grade ristocetin A) which may 
produce a stable crystalline forin. The first crystals of ristocetin A 
complexed to Ac-D-ala-D-ala were also obtained from the water/75% acetone 
system al though in this case it was the enormous size of the unit cell 
("'140,000A3) which prevented a crystal structure being obtained. Crystals 
of ristocetin A complexed to Ac2L-lys-D-ala-D-ala were also obtained but 
these were unstable upon storage and were not analysed further. Attempted 
crystallisations of the ristocetin A \J.1-aglycone derivative were 
completely without success. 
[1] See table 8.3 
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7.3 TRIOSTIN A 
The two conformers of triostin A have been studied using 1nmr. The 
previously proposed conformation of triostin-p (favoured in polar 
solvents) has been confirmed but the conformation of triostin-n (favoured 
in non-polar solvents) is shown to be considerably different to that of 
triostin-p or the previous proposal for triostin-n. 
Triostin-p may be considered to be a flat disc, with the peptide 
backbone around the edge, cross-bridged by a disulphide bond. The two 
quinoxaline ring systems are on the same side, termed the upper face, 
along with the val-N-Me and ala-CO. The remaining cys-N-Me, cys-CO and ser-
CO are on the lower face. The val-CO, involved in an ester linkage to the 
seryl residue is assumed to be in a trans orientation in the plane of the 
disc. The cross-bridge retains a large amount of flexibility and cannot be 
described by any one conformer. 
The largest nOe's observed in triostin-n between non-geminally 
coupled nuclei involved the val-aCH and cys-aCH protons. In order to 
reconcile this and other observed effects with the conformation in 
solution of triostin-n a globular structure is proposed. With the aid of a 
CPK model it can be appreciated that the close approach of the two protons 
noted above can readily be accomplished by conversion of the val-cys amide 
bond from a trans to a cis configuration. In addition, the alanyl residues 
on opposite sides of the disc are proximal and hydrogen bonding between 
them is postulated . 
Since the addition of 25% dmso to triostin in chloroform solution 
results in the complete conversion of triostin-n to triostin-p the 
conformation o~ the former is unimportant with respect to its antibiotic 
action and the intercalation with DNA, both of which only occur in aqueous 
solution. However, the conformation of triostin-~ does provide evidence of 
the flexibility of the molecule in solution. 
7.4 NMR SPECTROSCOPY 
As a consequence of the antibiotic studies nmr methods were 
developed in order to modify chemical exchange phenomema and to manipulate 
the nOe. The attainment of slow exchange conditions for vancomycin/Ac-D-
ala- D-ala was accomplished by the use of mixed solvent systems. This 
reduced the temperature at which · experiments could be performed, and in 
addition increased the lipophilic nature of the solvent thereby 
decreasing solvent exchange with the sample molecules. The nOe was 
effectively manipulated (towards the negative regime) by the use of the 
viscous oil Voltalef 10S. Considerably enhanced effects were observed (2% 
positive nOe's were converted to up to 73% negative nOe's) and. in addition 
the chemical equilibrium between the two conformers of triostin-A was 
affected by the increased viscosity and the increased lipophilic nature of 
the sol vent. The techniques developed would al so have application in 
similar studies of other antibiotics and could potentially yield 
structural information relating to the solution situation in an analogous 
manner to that provided in the solid state by the widely used x-ray 
crystallography methods. 
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8. EXPERIMENTAL 
Samples of ristocetin A were kindly supplied by Lundbeck Company, 
Copenhagen, Denmark. Commercial samples of vancomycin hydrochloride (Eli 
Lilley Inc. USA) were purchased and used without further purification. 
Samples of triostin A were kindly supplied by Mr A.Cornish and Dr 
M.J.Waring, Department of Pharmacology, University of Cambridge Medical 
School, Cambridge. The oil Voltalef 10S was a kind gift from Pechiney Ugine 
Kuhlmann, Paris, France. The following compounds were purchased, D-alanine 
( BDH), L-lysine hydrochloride ( BDH), D-alanyl-D-alanine ( Ba chem Inc. USA, 
and Uni science of Cambridge), di-carboJ?enzoxy-L-lysine (Sigma Chemicals 
Ltd.), t-butyl-ox ycarbonyloxyimino-2-phenylacetoni trile ( Aldrich Ltd.), 
Sephadex G-25 (Pharmacia Fine Chemicals). All other compounds used were 
readily available standard laboratory reagents ( generally of 'Analar' 
grade) which were used without purification, unless otherwise stated. Most 
solvents were dried and redistilled before use. 
Analytical TLC was performed on Merck plates coated with silica 
GF254 , the results being visualised with a UV lamp (where applicable). The 
abbreviation BWA refers to the n-butanol/water/acetic acid (3:1:1) elution 
system which was used extensively. Various methods of visualisation were 
tested for use with the synthetic peptide studies including a simple 
iodine jar (a few crystals of iodine were placed in the bottom of a jar 
which was sealed after inclusion of the exposed plate) and the 
chlorine/starch/iodide method (the exposed plate was sprayed with 
chlorine gas and the reaction carried out for 40 minutes in a sealed 
bottle, the plate was then sprayed with starch (2%)/potassium iodide (2%) 
solution). Difficulties with visualisation were encountered with both of 
these methods and the standard protein statn, ninhydrin, was therefore 
employed77. The exposed plate was sprayed with concentrated hydrochloric 
acid (to hydrolyse the amide bonds) and left for 15 minutes, it was then 
covered with another glass plate (to prevent rapid evaporation of solvent) 
and heated at 100°c for 30 minutes, after which the glass cover was removed 
and heating was continued for a further 10 minutes. Visualisation was 
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effected by spraying the plate with ninhydrin (0.5% in n-butanol) and 
heating to 100°c, orange/brown spots developed by reaction with primary 
amino groups. 
8.1 PREPARATIONS 
8. 1. 1 AC-D-ALA-D-ALA 
D-ala-D-ala (285mg) was dissolved in minimal water (2.5ml), 
distilled acetic anhydride (2ml) was added to this solution. Although 
immiscible at first a clear solution slowly formed with stirring for 30 
minutes. Rotary-evaporation at 50°c was used to remove solvent and produce 
an oil which was redissolved in distilled water and freeze-dried. A gummy 
solid was formed with the distinctive smell of acetic acid, this impurity 
was confirmed by nmr. Removal of acetic acid was performed using rotary-
evaporation at 70°c for 1 hour, redissolution of the residue in water and 
freeze-drying produced a white fluffy powder which had no visible 
impurities by nmr. 
Yield: 350mg (98%) 
1H nmr ( 100MHz, dmso-d6, 90°c) 0 1.22 ( d, 3J7.3Hz; 3H, ala 2Me ), 1.27 ( d, 
3J7.5Hz, 3H, ala 1Me ) , 1.85 ( s, 3H, acetyl-Me ), 4.20 ( m, 3J7.3Hz, 1H, 
ala 1CH ), 4.33 ( m, 3J7.3Hz, 1H, ala2cH ), 8.05 ( d, 3J7.3Hz, 1H, ala2NH ), 8.18 ( d, 3J7.3Hz, 1H, ala 1NH ). The 400MHz spectrum is shown in figure 8.1. 
8. 1.2 N-HYDROXYSUCCINIMIDE 
Succinic anhydride ( 100g) and hydroxyla-mine hydrochloride (70g) 
were slowly heated on an oil-bath, using a rotary-evaporator in order that 
volatile products could be conveniently trapped in liquid nitrogen. When 
the initial evolution of gases had ceased the temperature was raised to 
125°c where fusion occurred with further evolution of gases. The 
temperature was slowly raised to 160°c where, upon cessation of the 
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evolution of water, heating was discontinued. At 125°C the amber liquid was 
poured into diethyl ether (400ml) which was vigorously stirred. The solid 
residue which formed was heated to boiling with n-butanol (400ml) after 
decantation of the diethyl ether. Filtration and chilling of the filtrate 
caused the slow crystallisation of N-hydroxysuccinimide which was washed 
with n-butanol and diethyl ether. Recrystallisation from boiling ethyl 
acetate gave a white solid. 
Yield: 0.24g (20%) Mel ting Point :98° ± 1 °c 
1H nmr ( dmso- d6, 100MHz, 30°c ) o 2.62 ( s, 4H, 2xCH2 ); compare with 
succinic anhydride under the same conditions, O 2.95 ( s, 4H, 2xCH 2 ). 
8. 1.3 t-BUTYLOXYCARBONYL-D-ALANINE 
This single-pot reaction of D-alanine (0.89g), t-butyl-
oxycarbonyloxyimino-2-phenylacetonitrile (t-BOC-ON, 2.71g), triethylamine 
(2.10ml), water (6ml) and 1,4-dioxane (6ml), involved warming to 40°C and 
stirring for l hours. The t-BOC-D-alanine was isolated from the oxime by-
product by diluting with water ( 15ml) followed by addition of ethyl 
acetate (20ml). The yellow aqueous layer, containing the protected amino 
acid, was separated and washed with further portions of ethyl acetate to 
produce a colourless liquid. Acidification to pH1 with dilute hydrochloric 
acid (3M) was followed by extraction into ethyl acetate. The volume of the 
ethyl acetate solutibn was reduced by rotary-evaporation before 
crystallisation was effected by the addition of n-hexane. 
Recrystallisation was also performed using ethyl acetate/n-hexane. 
Yield: 0.83g (50%) Mel ting Point: 82°± 0. 5°c 
1H nmr ( 100MHz; dmso-d6, 30°c ) 01.23 ( d,3J7.2Hz, 3H, alaMe ), 1.40 ( s, 9H, 
t-butyl ) , 3.83 ( m, 3J7. 1Hz, 1H, al a CH ) , 7.80 ( broad, 1H, alaNH ) . 
8. 1.4 D-ALANINE BENZYL ESTER - 1 
Polyphosphoric acid (5g), prepared by dissolving phosphorous 
pentoxide (3.6g) in · orthophosphoric acid (2ml), was stirred and warmed 
alor.g with benzyl alcohol (25ml) until a homogeneous solution resulted. D-
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alanine (1.1g) was added and the solution heateo to 90°c, stirring was 
continued for 4 hours. The solution was acidified by pouring into water 
(200ml) containing concentrated hydrochloric acid ( 10ml). The aqueous 
phase of the amino acid benzyl ester hydrochloride was extracted with 
diethyl ether and the latter washed with dilute hydrochloric acid (2%). 
The aqueous extracts were combined and sodium hydrogen carbonate added to 
adjust to pH10. The free base was extracted into diethyl ether (3x100ml) 
and dried over anhydrous magnesium sulphate. Saturation of the ethereal 
solution with dry hydrogen chloride gas precipitated D-ala benzyl ester 
hydrochloride as a clear oil. Residual sol vents were removed by rotary-
evaporation. Purification by crystallisation was unsuccessful from 
methanol/diethyl ether or ethanol/n-hexane or ethanol/ethyl acetate. The 
nmr spectrum of the oil showed minor splitting (2Hz) of the alanine methyl 
doublet, probably due to racemization, which would explain the 
difficulties encountered in purification. 
Yield: 2.14g (98%) oil. 
8.1.5 D-ALANINE BENZn. ESTER p-TOLUENE SULPHONIC ACID SALT 
This is essentially a one-pot reaction where D-alanine (0.56g), p-
toluene sulphonic acid (1.21g), benzyl alcohol (2.5ml) and benzene (25ml) 
are refluxed overnight ( 15 hours). The use of a Dean-Stark tube proved 
efficient in removing the water of esterification as the azeotrope with 
benzene. The reaction mixture was cooled and dry diethyl ether (50ml) was 
added . to induce crystallisation by reducing the product solubility; 
chilling in ice was found to be helpful in this respect. Recrystallisation 
was readily achieved from methanol/diethyl ether. 
Yield: 1.93g (88%) Mel ting Point: 108° ± 0.5°C 
1H nmr ( 100MHz, dmso-d6, 4o 0 c) 61 .44 ( d, 3J7.1Hz, 3H, alaMe ), 2.31 ( s, 
3H, tosylMe ), 4.20 ( q, 3J7.0Hz, 1H, alaCH ), 5.27 ( s, 2H, benzylCH2 ), 7.12 
( d, 3J8. 0Hz, 2H, tosyl ), 7.42 ( m, 5H, benzyl ), 7.51 ( d, 3J8.2Hz, 2H, tosyl 
) , 8.33 ( broad, 1H, alaNH ). 
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8. 1.6 D-ALANINE BENZYL ESTER - 2 
D-alanine benzyl ester p-toluene sulphonic acid salt (2.5g) was 
dissolved in chloroform ( 15ml), triethylamine ( O. 75ml) was then added to 
liberate the D-ala benzyl ester free base. The reaction proceeded for 30 
minutes and then diethyl ether was added to precipitate the 
triethylamine/tosylate salt. The clear solution, obtained after 
filtration, was rotary-evaporated to dryness. The resulting gel started to 
crystallise and was aided by the addition of petroleum ether (boiling 
range 4o 0 -6o 0 c). 
Yield: 0.52g (41 %) Mel ting Point: 97° :!: 10°c 
The 1H nmr spectrum showed the crystalline product to be a mixture of the 
free base and the tosyl salt of D-ala benzyl ester in an approximate ratio 
of 1:2. 
An alternative approach proved more successful. D-alanine benzyl 
ester p-toluene sulphonic acid salt (30mg) was dissolved in water (0.5ml) 
and sodium hydrogen carbonate added until pH9 was attained. The free base 
was extracted into diethyl ether and dried over magnesium sulphate. 
Removal of the solvents by rotary-evaporation produced an oil which 
crystallised upon the addition of petroleum ether (boiling range 40°-
6o0c). 
Yield: 14mg 
1H nmr ( 100MHz, dmso-d6, 30°c ) 01.21 ( d, 3J7.0Hz, 3H, alaMe), 3.49 ( q, 
3J7.0Hz, 1H , alaCH ) , 5. 13 ( s, 2H, benzylCH2 ), 7. 38 ( m, 5H, benzyl ). 
8.1. 7 D-ALANYL-D:-ALANINE BENZYL ESTER - 1 
Polyphosphoric acid (5g) [1 J , was warmed with benzyl alcohol 
(2.5ml) until a homogeneous solution resulted. ·o-alanyl-D-alanine (0.2g) 
was added and the solution heated to 90°c, stirring was continued for 4 
hours. The solution was further acidified by pouring into water (20ml) 
[1] Preparation described above 
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containing concentrated hydrochloric acid (1ml) . The aqueous phase, 
containing the hydrochloride of the amino acid benzyl ester, was extracted 
with diethyl ether and the latter washed with dilute hydrochloric acid 
(2%). The aqueous extracts were combined and sodium hydrogen carbonate 
added to pH10. The free base was extracted into diethyl ether (3x10ml) and 
dried over anhydrous magnesium sulphate. Saturation of the ethereal 
solution with dry hydrogen chloride gas produced a thick white oily 
precipitate. Solvents were removed by rotary-evaporation to yield a clear 
oil which was immiscible with water (and hence unlikely to be the expected 
hydrochloride salt). Attempted crystallisation from methanol/diethyl 
ether proved unsuccessful. It appeared from the nmr data that the spectrum 
of benzyl alcohol [2] was superimposed upon that of D-alanyl-D-
alanine [ 3 J 
8.1.8 D-ALANYL-D-ALANINE BENZYL ESTER p-TOLUENE SULPHONIC ACID SALT 
D-ala-D-ala benzyl ester p-toluene sulphonic acid salt was prepared 
in a similar manner to that successfully used for the single amino acid D-
alanine. The dipeptide D-alanyl-D-alanine (0.4g), p-toluene sulphonic acid 
(0.49g), benzyl alcohol (1.5ml) and benzene (25ml) were refluxed for 16 
hours with stirring. A Dean-Stark tube was used for the removal of the 
water of esterification as the azeotrope with benzene. The addition of 
diethyl ether to the cool reaction mixture and further chilling in an ice 
bath produced a white crystalline product which was recrystallised from 
methanol/diethyl ether. 
Yield: 0.96g (91 %) Mel ting Point: 162° ± 1 °c 
1H nmr ( 100MHz, dmso-d6, 4o 0 c) 0 1.34 ( d, 3J7.0Hz, 3H, ala2Me ), 1.37 ( d, 
3J7.4Hz, 3H, ·~la 1Me ), 2.31 ( s, 3H, tosylMe ), 4.40 ( m, 3J7.2Hz, 1H, a l a 1CH ), 
4.48 ( m, 3J7.2Hz, 1H, ala2CH ), 5.16 ( s, 2H, benzylCH2 ), 7.13 ( d, 3J7.7Hz, 
2H, tosyl ), 7.38 ( m, 5H, benzyl) 7.51 ( d, 3J8.3Hz, 2H, tosyl ), 8.08 ( 
[2] 
[3] 
1 
. H nmr ( 100MHz, CDC1 3, 30°c ) 04.60 ( s, 2H, benzylCH 2 ), 7.35 ( m, 5H, benzyl ) • 
1H nmr ( 100MHz, CDCl , 30°c ) 01 .18 ( d, 3J7.1Hz, 3H, ala2Me ), 1.25 ( d, 3J7.0Hz, 3H, ala 1~e ) , 3.41 ( m, 3J7.0Hz, 1H, ala 1CH ), 3.55 ( m, J7.0Hz, 1H, ala 2CH ), 4.60 ( s, 2H, benzylCH 2 ), 7.32 ( m, 5H, benzyl ). 
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broad, 2H, ala2NH ), 8. 78 ( d, 3J7.0Hz, 1H, ala 1NH ) 
TLC in 10% methanol in chloroform el uant produced a single spot, RF0.20. 
8.1.9 D-ALANYL-D-ALANINE BENZYL ESTER - 2 
A solution of D-ala-D-ala benzyl ester p-toluene sulphonic acid 
salt (100mg) in water (0.5ml) was adjusted to pH9 by the addition of sodium 
hydrogen carbonate. After 45 minutes the dipeptide free base was extracted 
into diethyl ether and dried over anhydrous magnesium sulphate. Removal of 
the solvent produced an oil which was identified by its 1H nmr spectrum to 
be essentially starting material. 
8.1.10 L-ALANINE BENZYL ESTER HYDROCHLORIDE 
The conversion of L-alanine benzyl ester p-toluene sulphonic acid 
salt (3.5g) into the hydrochloride was effected by dissolving the former 
in chloroform (15ml) at o0-s 0 c, triethylamine (1g) was then slowly added 
with stirring. The absence of water at this stage was found to be 
imperative for successful reaction and was readily checked using nmr. The 
reaction was allowed to proceed for 1 hour and then dry diethyl ether 
(50ml) was added to precipitate the ammonium tosylate by-product which was 
subsequently filtered off. Dry hydrogen chloride gas was bubbled through 
the solution to cause precipitation of L-ala benzyl ester hydrochloride 
which was filtered and washed with dry diethyl ether. Recrystallisation 
from methanol/diethyl ether proved unsuccessful. 
Yield: 1.27g (59%) 
1H nmr ( 100MHz, dmso-d6, 30°c) 6 1.46 ( d, 3J7.1Hz, 3H, alaMe), 4.18 ( m, 
3J7.2Hz, 1H, alaCH ), 5.26 ( s, 2H, benzylCH 2 ), 7.42 ( m, 5H, benzyl ), 8.59 
( broad, 1H, alaNH ). 
8.1. 111 N,N 1-DI-ACETYL-L-LYSINE 
L-lysine hydrochloride (0.88g) was dissolved in . water (5ml) and 
acetic anhydride (5ml) was added. Reaction proceeded for 1 hour then 
rotary-evaporation was used to remove the solvents , leaving an oil. 1H nmr 
analysis of this oil identified L-lysine starting material and acetic 
acid. 
The most obvious reason for reaction failure was the possible 
protonation of the primary amino groups when present as the hydrochloride 
salt. Therefore L-lysine hydrochloride (1g) was dissolved in water (2ml) 
and potassium carbonate added to adjust to pH10 (from pH7). Acetic 
anhydride (3ml) was added and reaction allowed to proceed for 6 hours, 
dilute hydrochloric acid (3M) was then added to adjust to pH1. Extraction 
into diethyl ether or chloroform proved unsuccessful, as did 
crystallisation from methanol/diethyl ether. 
Yield: 1.09g oil 
1H nmr ·showed secondary splitting (2Hz) of the lys-CH proton indicating 
that racemization had probably occurred about this centre. 
TLC in BWA el uant gave three spots, RF O. 7, 0.3 and 0. 0, presumably from the 
diacetyl, monoacetyl and unprotected lysine respectively. 
8. 1. 12 DI-t-BOC-L-LYSINE 
L-lysine hydrochloride (0. 7.3g), t-butyl-oxycarbonyloxyimino-2-
phenylacetoni trile (2.71g), triethylamine (1.05ml), 1,4-dioxane (3ml) and 
water (3ml) were mixed together, a further amount of 1,4-dioxane (6ml) was 
necessary in order to dissolve the components. The solution changed colour 
from yellow to brown after stirring for 20 minutes of the 3 hours at 4o 0 c. 
The di-t-BOC-L-lysine was isolated from the oxime by-product by diluting 
with water ( 6ml) followed by the addition of ethyl acetate ( 8ml). The 
aqueous layer, containing the protected amino acid, was separated and 
washed with further portions of ethyl acetate. Acidification to pH1 with 
dilute hydrochloric acid (3M) was followed by extraction into ethyl 
acetate. The volume of ethyl acetate was reduced by rotary-evaporation. 
Crystallisation, by the addition of n-hexane, was unsuccessful. 
Yield : 0.55g (36%) 
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Analytical TLC, eluting with 10% methanol in chloroform, gave a single 
spot, RF0.80. However, in BWA three spots were obtained, RF0.80, 0.40 and 
0.00, presumably due to di-protected, mono-protected and un-protected L-
lysine. The estimated conversion was 50% to the di-protected L-lysine. The 
nmr spectrum showed many impurities, further purification was therefore 
necessary. 
The dicyclohexylcarbodiimide (DCC) derivative of di-t-BOC-L-lysine 
was thought likely to give a crystalline product. However upon reaction of 
the crude di-t-BOC-L-lysine oil, dissolved in diethyl ether, with a slight 
excess of ethereal DCC, only unchanged crystalline DCC was recove"red. 
Purification of this derivative was not pursued further; the purchase of 
N,N 1-di-CBZ-L-lysine was considered more pertinent to the ultimate 
synthetic goal. 
8. 1. 13 DI-t-BOC-L-LYSINE SUCCINIMIDE ESTER 
A crude preparation of di-t-BOC-L-lysine (0.5g) was dissolved in 
ice-cold 1,2-dimethoxyethane (10ml). N-hydroxysuccinimide (0.17g) was then 
added followed by dicyclohexylcarbodiimide (0.31g). The solution was 
stored at 3°c for 42 hours during which time the urea by-product 
precipitated from solution. Filtration and rotary-evaporation at 50°c of 
the filtrate produced an oil. 
Yield: 0.46g (73%) 
Analytical TLC in BWA eluant gave four spots, RF0.92, 0.68, 0.48 and 0.00; in 
10% methanol in chloroform five spots were obtained, RFO. 73, 0.61, 0.36, 0.15 
and 0.00. 
1H nmr showed the major component of the oil to be the crude di-t-BOC-L-
lysine starting material. 
8. 1. 14 N,N 1-DI-CBZ-L-LYSINE SUCCINIMIDE ESTER 
N-hydroxysuccinimide (0 .57g) was added to a. solution of N,N 1-di-CBZ-
L-lysine (2.0g) in 1,2-dimethoxyethane (5ml), which in turn was chilled and 
added to a dispersion of dicyclohexylcarbodiimide (1.30g) in 1,2-
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dimethoxyethane (15ml) and chloroform (4ml) - . this solvent system was 
found to be preferable to 1,4-dioxane. The urea by-product precipitated 
within minutes and was filtered off to give a clear filtrate. Rotary-
evaporation to remove the solvents produced an oil which crystallised from 
methanol/diethyl ether. Vacuum filtration and drying over phosphorous 
pentoxide/sodium hydroxide gave a white crystalline product. 
Yield: 1.88g (76%) Melting Point: 113° ± 0.5°c 
1H nm~ ( 100MHz, dmso-d6, 30°c ) 0 1.44 ( broad, 4H, lysCH 2 ), 1.80 ( broad, 
2H, lysCH 2 ), 2.83 ( s, 4H, succinimide ), 3.01 ( q, 3J5.8Hz, 2H, lysCH2 ), 4.43 
( q, 3J6.8Hz, 1H, lysCH ), 5.03 ( s, 2H, benzylCH 2 ), 5.09 ( s, 2H, benzylCH2 ), 
7.23 ( t, 1H, lysNH ), 7.36 ( m, 5H, benzyl ), 7.37 ( m, 5H, benzyl ), 8.05 ( d, 
3J7.2Hz, 1H, 1 ysNH ) . 
The nmr spectral parameters of di-CBZ-L-lysine under the same 
conditions are given below for comparison. 
1H nmr 0 1.25 ( broad, 1H, lysCH 2 ), 1.36 ( broad, 4H, lysCH2 ), 1.64 ( broad, 
1H, lysCH 2 ), 2.97 ( q, 3J6.0Hz, 2H, lysCH 2 ), 3.75 ( q, 3J5.9Hz, 1H, lysCH ), 
5.02 ( s, 4H, benzylCH 2 ), 7.24 ( t, 1H, lysNH ), 7.35 ( m, 11H, benzyl+lysNH ). 
TLC using 10% methanol in chloroform produced a single spot with RF0.77. 
8. 1. 15 N,N 1 -DI-CBZ-L-LYS-D-ALA BENZn. ESTER 
A solution of di-CBZ-L-lys succinimide ester (143mg) in 1,2-
dimethoxyethane (1ml) was added to a dispersion of D- ala benzyl ester p-
toluene sulphonic acid salt (50mg) in 1,2-dimethoxyethane (1ml). A 
precipitate formed immediately and was subsequently identified as the 
lysine star\ing material. A slightly modified experimental procedure was 
found to be successful. The D-ala benzyl ester p-toluene sulphonic acid 
salt (75mg) was dissolved in water (0.5ml) containing sodium hydrogen 
carbonate (84mg). This solution was then added to a solution containing 
di-CBZ-L-lys succinimide ester (214mg) dissolved in 1,2-dimethoxyethane 
( 1. 7ml). Combination of the two solutions resu1 ted in immediate 
precipitation. The residue from filtration was dried over phosphorous 
pentoxide/sodium hydroxide to give a white solid. 
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Yield: 152mg (63%) Mel ting Point: 160° ± 2°c 
1H nmr ( 100MHz, CD 2c12, 30°c) 0 1.40 ( d, 3J7.0Hz, 3H, alaMe ), 1.0-2.0 
( broad, 6H, lysCH 2 ), 3.18 ( q, 3J6.0Hz, 2H, lysCH 2 ), 4.15 ( q, 3J6.0Hz, 1H, 
lysCH ), 4.57 ( m, 3J7.0Hz, 1H, alaCH ), 5.08 ( s, 2H, benzylCH2 ), 5.12 ( s, 2H, 
benzylCH 2 ), 5.18 ( s, 2H, benzylCH2 ), 6.57 ( d, 1H, alaNH ), 7.35 ( m, 10H, 
benzyl ), 7.37 ( m, 6H, benzyl+lysNH ). 
m/e 575 (M+); calc. 575. 
8.1. 16 N,N 1-DI-CB2-L-LYS-D-ALA-D-ALA BENZYL ESTER 
The dipeptide D-ala-D-ala benzyl ester p-toluene sulphonic acid 
salt (0.5g) was dissolved in water (2ml) and sodium hydrogen carbonate 
added to adjust to pH9. Immediate precipitation resulted upon the addition 
of a solution of di-CBZ-L-lys succinimide ester (0.61g) in 1,2-
dimethoxyethane (5ml). Filtration and drying of the residue over 
phosphorous pentoxide/sodium hydroxide produced a light white powder. 
Yield: 0.75g (98%) Mel ting Point: 159° ± 1 °c 
TLC using 10% methanol in chloroform as eluant produced a single spot, 
RF0.79; using BWA a single spot was also obtained with RF0.89. 
1H nmr ( 100MHz, dms~-d6, 30°c ) 01 .16 ( d, 3J8.0Hz, 3H, alaMe ), 1.32 ( d, 
3J8.0Hz, 3H, alaMe ), 1.0-1.8 ( broad, 6H, lysCH 2 ), 2.97 ( q, 3J6.0Hz, 2H, 
lysCH 2 ), 3.50 ( broad, 1H, alaCH ), 4.00 ( q, 3J7.0Hz, 1H, lysCH ), 4.34 ( m, 
3J7.0Hz, 1H, alaCH ) , 5.02 ( s, 2H, benzylCH2 ), 5.13 ( s, 2H, benzylCH2 ), 7.14 
( d, 1H, alaNH ), 7.36 ( m, 10H, benzyl ), 7.38 ( m, 6H, benzyl+lysNH), 8.02 
( d, 3J8.0Hz, 1H, lysNH ), 8.26 ( d, 3J7.0Hz, 1H, alaNH ). 
8. 1. 17 N,N 1 -AC2-L-LYS-D-ALA-D-ALA 
A solution of di-CBZ-L-lys-D-ala-D....:a1a benzyl ester (0.84g) was 
dissolved in concentrated aqueous acetic acid (80%, 100ml) and then 
hydrogenated for a minimum of 6 hours in the presence of palladium (10%) 
on charcoal ( 1.Jg) catalyst. Filtration followed by rotary-evaporation at 
6o 0 c produced a clear, partially crystalline oil ( 1.33g) which was then 
dissolved in water (1ml) and acetylated by reaction for 1 hour with acetic 
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anhydride (3ml). Rotary-evaporation at 70°c, until .all traces of acetic 
acid had been removed, resulted in an oil. Several crystallisation systems 
were tried, including i-propanol/acetone, ethyl acetate/carbon 
tetrachloride, i-propanol/carbon tetrachloride, ethanol/petroleum ether 
(boiling range 40°-6o 0 c) and ethanol/n-hexane. The last mentioned of these 
systems had been successfully employed for this purpose by Nieto and 
Perkins during their extensive binding studies on vancomycin and 
ristocetin, however in this laboratory it was found to be as unsuccessful 
as the others. The one system which could be used was ethanol/diethyl 
ether, the problem being that the precipitated product was found to be 
exceedingly soluble in ethanol, and unless excess ether was present during 
filtration resolvation occurred with concommitant loss of product . The 
white powder was dried over phosphorous pentoxide/sodium hydroxide. 
Yield: 0.31 g (64%) 
TLC in BWA eluant · produced a single spot, RF0.16, in 10% methanol in 
chloroform a single spot with RF0.08 was obtained. A further solvent system 
which proved particularly sensitive in this experiment was chloroform/t-
amyl-alcohol/methanol/acetic acid in the ratio 40:30:30:3, producing a 
single spot with RF0.25. On occasion trace impurities of mono-acetyl 
tripeptide were detected in which case it was found expedient to pass the 
preparation, dissolved in dilute acetic acid (6%), down an ion-exchange 
column (Amberlite IR-120, H+ form, BDH Ltd.). 
1H nmr, figure 8.2(coupling constants from 100MHz, shifts from 400MHz, 
dmso-d6, 30°c ) 01 .19 ( dd, 3J6.7 and 7.0Hz, 6H, alaMe's ) , 1.25 ( m, 2H, 
lys Y CH 2 ), 1.36 ( m, 2H, lys 6 CH 2 ), 1.52 and 1.58 ( m, 1H+1H, lys pcH2 ), 
1.79 ( s, 3H, AcMe ), 1.86 ( s, 3H, AcMe ) ,2.99 ( q, 3J6.3Hz, 2H, lys £ CH 2 ), 
3.83 ( m, 3J7.0H.z, 1H, ala 1CH ) , 4.23 ( m, 2H, lysCH + ala2CH ), 7. 64 ( d, 
3J7.0Hz, 1H, ala2NH ), 7.95 ( t, 3J6.2Hz, 1H, lys £ NH ), 8.06 ( d, 3J7.5Hz, 1H, 
lys aNH ), 8.17 ( d, 3J7.5Hz, 1H, ala 1NH ). 
Further characterisation was obtained from mass spectral evidence. The 
electron impact spectrum at 200°c of the permethyl~ted tripeptide 
produced a m/e 442(M+), 326(M+-ala), 241 (M+-ala-ala), 178 m*(326-241 ). The 
spectrum of the perdeuteriomethylated tripeptide produced a similar 
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fragmentation pattern, m/e 457 (M+), 335 (M+-ala), 247 (M+-ala-ala). 
8.1.18 RISTOCETIN IODIDE SALT 
Ristocetin A ( O. 18g), supplied as the hydrogen sulphate salt, was 
dissolved in water (3ml) and a solution of barium iodide (0.12g) in water 
(4ml) was added. A white precipitate formed immediately. The suspension 
was centrifuged (--1000xg, 20 minutes) to give a clear supernatant which 
was readily decanted from a hard white pellet of barium sulphate. Freeze-
drying of the supernatant produced a pale yellow, light powder of 
ristocetin A iodide salt (confirmed by standard chemical tests). 
8.1.19 RISTOCETIN- \1.J -AGLYCONE 
Ristocetin A (300mg) was heated under reflux in methanolic hydrogen 
chloride (5%, 15ml) for one hour. The volume was reduced to near-dryness 
(.-0.5ml) and the residue redissolved in water (10ml). A solution of 
potassium carbonate ( 1M) was added to adjust to pH 7.5, at which point 
precipitation of crude \I.J -aglycone occurred. The precipitate was separated 
by centrifugation, redissolved in a minimum volume of aqueous acetic acid 
(6%) and applied to a gel-filtration (Sephadex G-25) column (1x120cm). The 
column was eluted with acetic acid (6%, 18ml/hour). An ultra-violet 
absorbing (280nm) component was eluted after 7.5 hours. 
The eluate was freeze-dried to give the required product (80mg) 
which was found to be pure by TLC ( BWA, RFO. 55) and by HPLC ( Bondapak Cl 8 
column, eluted with 0.05M KH 2Po 4/MeCN, 3:1, 2ml/minute). 
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8.2 CRYSTALLISATION STUDIES 
8.2. 1 TECHNIQUES 
Of the techniques generally available78 two in particular were used 
extensively and are described below. 
(1) 1Ihe Layering Method 
A suitable precipitant was placed in a tube and then, with the aid of 
a hypodermic needle and syringe, a small amount of sample was very slowly 
injected beneath the precipitant layer. The latter had to be less dense 
than the sample solution and miscible with it. A ratio of 1:4 sample 
solution:precipitant was typically used, with sample volumes of 0.2ml. The 
tube was sealed and left undisturbed for various periods of time. 
Diffusion of the precipitant into the sample produced, if successful, 
crystals at the interface of the two solutions. An alternative method of 
applying the precipitant directly to the surface of the sample solution 
produced excessive disturbance of the interface. 
(2) Vapour Diffusion 
The principle is essentially the same as for the layering method but 
the precipitant is allowed to diffuse into the solution from the vapour 
phase. The sample solution (usually 0.2ml) was placed in an unsealed vial 
(0.5dram) which in turn was placed in. a larger vial (3dram), containing the 
volatile precipitant, which was then sealed. Crystal formation was slower 
than for the layering method but improved crystal quality was often 
attained with this method. The main parameters which· were varied were 
temperature, concentration of antibiotic and of course the solvent system. 
8.2.2 VANCOMYCIN 
Vancomycin is soluble in water and dmso, sparingly soluble in 
ethanol and methanol, and insoluble in chloroform and carbon 
tetrachloride. Experiments were therefore performed with solutions of 
vancomycin in either water or dmso. 
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Vancomycin (50mg) was dissolved in water (1ml) and a duplicate 
sample in dmso (1ml). Five equal portions of each of these solutions were 
used for vapour diffusion experiments with various solvents. The results 
after one week are shown in table 8. 1. 
Table 8.1 Vancomycin Crystallisation Experiments 
Sample Sol vent Precipitant Result 
water acetone pptn 
water methanol pptn 
water ethanol pptn 
water i-propanol pptn 
water DME pptn 
dmso acetone pptn+amres 
dmso CHC1 3 pptn 
dmso CH 2c1 2 pptn+amres 
dmso CC1 4 oily residue 
Abbreviations: pptn=precipitation, amres=amorphous residue, 
DME=1,2-dimethoxyethane. 
All experiments were performed at 20°c. 
8.2.3 VANCOMYCIN/AC-D-ALA-D-ALA 
Vancomycin (73mg) and Ac-D-ala-D-ala (10mg) were dissolved in water 
( 1 ml). A viscous solution (pH2.4) was obtained which precipitated above 
pH3. Incubation under conditions similar to those which produced the 
crystals of CDP-I were tried (8o 0 c for 16 hours) but produced a gel only. A 
similar result was obtained with a more dilute solution of vancomycin 
(28mg) and Ac-D-ala-D-ala (4mg). 
Vancomycin (25mg) and Ac-D-ala-D-ala (3mg) were dissolved in water 
(1ml). a duplicate sample was dissolved in dmso (1ml). Each solution was 
divided into five equal portions which were the~ used for vapour diffusion 
experiments (25°C) with various solvents. The results obtained after two 
weeks are shown in table 8.2. 
Table 8.2 Vancomycin/Ac-D-ala-D-ala Crystallisation Experiments 
Sample Solvent Precipitant Result 
water acetone pptn 
water 80% acetone neg 
water methanol pptn 
water i-propan.ol pptn 
water CH 2c12 pptn 
dmso acetone pptn 
dmso 80% acetone neg 
dmso methanol pptn 
dmso CC1 4 amres 
dmso CH 2c12 amres 
Abbreviations: pptn=precipitation, neg=no residue, 
amres=amorphous residue. 
All experiments were performed at 20°c. 
8.2.4 RISTOCETIN A 
Ristocetin A was found to be soluble in 95% methanol or 70% ethanol 
or 70% acetone. In addition, aqueous solutions with ristocetin 
concentrations of up to 20% were readily prepared. The results of many 
experiments, performed at 20°c unless otherwise stated, are shown in table 
8.3. 
Table 8.3 Ristocetin A Crystallisation Experiments 
Risto(mg) Sample Solvent Precipitant Method Result(days) 
5 70%acetone acetone VD pptn(21) 
5 70%EtOH acetone VD amres(21) 
5 95%Me0H acetone VD amres(21) 
5 water acetone VD pptn(7) 
5 70%acetone 95%Et0H VD neg(40) 
5 70%EtOH 95%Et0H VD neg(40) 
5 95%MeOH 95%Et0H VD neg(40) 
5 water 95%EtOH VD neg(40) 
15 70%Et0H 95%Et0H L neg(7) 
5 70%EtOH 95%EtOH L neg(24) 
5 70%Et0H acetone L neg(24) 
5 95%Me0H EtOAc L neg(91) 
5 70%EtOH EtOAc L pptn(91) 
5 water EtOAc L neg(91) 
5 70%acetone EtOAc L neg(91) 
5 95%Me0H acetone VD pptn(5) 
50 water 95%Et0H VD amres( 11), 5°c 
50 water 95%Et0H VD amres(7) 
50 water acetone VD pptn ( 10) , 5°c 
50 water acetone VD pptn(7) 
50 water MeOH VD pptn(11),5°c 
50 water MeOH VD pptn(7) 
50 water 75%acetone VD cryst(10) 
50 water MeOH VD amres(21) 
50 water 95%Et0H VD pptn(21) 
5+S water 75%acetone VD cryst(2) 
5 water 75%acetone VD cryst(4) 
10+S water 75%acetone VD cryst(2) 
25 water 75%acetone L cryst(3) 
10 water 75%acetone VD cryst(4) 
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Table 8.3 Continued 
Risto(mg) Sample Solvent 
10 water/MPD(3:1) 
50 water/MPD(4:1) 
50 water/MPD(2:1) 
50 water/MPD(4:3) 
50 water/MPD(1:1) 
50 water/MPD(4:5) 
50 water/MPD(2:3) 
10 water 
10 water 
10 water 
10 70%EtOH 
10 water 
10 water 
10 water 
10 water 
10 water 
10 water 
20 water/Me0H(6: 1) 
20 water/EtOH(6: 1) 
20 water/TFA(6:1) 
20 water/i-Pr0H(6:1) 
20 water/n-BuOH (6: 1) 
20 water/DMF(6:1) 
20 water/t-AmOH 
20 water 
600 water 
Precipitant Method 
MPD VD 
MPD VD 
MPD VD 
MPD VD 
MPD VD 
MPD VD 
MPD VD 
75%Et0H VD 
80%Et0H VD 
95%Et0H VD 
75%acetone VD 
Et0Ac/EtOH(9:1) L 
Et0Ac/EtOH(7:3) L 
EtOAc/EtOH(1:1) L 
Et0Ac/EtOH(3:7) L 
Et0Ac/Et0H(1:9) L 
Et0Ac/Et0H(1:99) L 
75%acetone VD 
75%acetone VD 
75%acetone VD 
75%acetone VD 
75%acetone VD 
75%acetone_ VD 
75%acetone VD 
75%acetone VD 
75%acetone VD 
Result(days) 
cryst( 11) 
cryst(12) 
cryst(12) 
cryst( 11) 
cryst( 12) 
cryst(12) 
cryst(12) 
neg(7) 
neg(7) 
neg(7) 
pptn(7) 
amres( 7) 
amres(7) 
amres(7) 
amres(7) 
amres(7) 
amres(7) 
cryst(5) 
cryst(5) 
cryst(5) 
cryst(5) 
cryst(5) 
cryst(5) 
cryst(5) 
cryst(13) 
cryst(38) 
Abbreviations: pptn=precipitation, amres=amorphous residue 
cryst=crystals, neg=no residue, S=seeded, VD=vapour diffusion, 
L=layering, MPD=2-methylpentan-2,4-diol, TFA=trifluoroacetic acid, 
DMF=dimetnylformamide, t-AmOH=t-amyl alcohol, i-PrOH=i-propanol, 
EtOAc=ethyl acetate, EtOH=ethanol, MeOH=methanol, 
n-BuOH=n-butanol, Risto=ristocetin A. 
Several systems produced crystalline residues although none except 
for the water/75% acetone system were considered of suitable quality for 
x-ray analysis. The crystals obtained from the water/75%acetone solvent 
system were generally in the form of multiple clusters . The size of these 
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clusters was reduced by using more dilute solutions of ristocetin A but 
single crystals (suitable for x-ray analysis) were not routinely produced. 
All crystallisations performed up to this point had used commercial 
ristocetin without further purification, however improved crystals were 
obtained with purified ristocetin. The multiple crystals of ristocetin A 
were harvested by decanting the mother liquor, dissolving in water, 
pooling many samples and then freeze-.drying. The whole cycle was repeated 
a further time and produced a white fluffy powder (commercial ristocetin A 
is pale brown in colour) which was used in subsequent crystallisations. 
The purified ristocetin A routinely produced single crystals from the 
water/75% acetone system and in greatly reduced times (within 2 days) 
al though a further two weeks was usually necessary in order to obtain 
crystals of suitable size. Further crystallisation experiments using this 
purified material are shown in table 8.4, although none produced crystals 
superior in quality to those from the water/75%acetone system. 
Table 8.4 Ristocetin A (purified) crystallisation Experiments 
Risto(mg) Precipitant Result(days) 
5 75%acetone cryst(2) 
5+S 75%acetone cryst( 1) 
3 ethanol pptn(34) 
3 95%ethanol pptn(34) 
3 85%ethanol pptn(34) 
3 methanol neg(34) 
3 95%methanol neg(34) 
3 80%acetone cryst(14) 
3 75%acetone cryst(14) 
3 80%i- propanol cryst(14) 
3 EtOAc neg(34) 
Abbreviations: Risto=ristocetin A, S:seeded, 
pptn=precipitation, cryst=crystals, neg=no residue, 
EtOAc=ethyl acetate. 
All experiments were performed at 20°c in aqueous 
solution with vapour diffusion of the precipitant. 
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Ristocetin A crystals from water/75Sacetone ~ Crystal Data 
The crystals were rhombic platelets which grew in stacks, often from 
a common edge. They were unstable in air and had to be enclosed in a glass 
capillary with some mother liquor present. The x-ray diffraction data was 
observable in part to .-90° with confirmed intensities at 2 9 =86°. The 
crystals were not amenable to isomorphous replacement and posed severe 
mounting problems. c95 H110N8o44 , monoclinic, space group P2 1, a:26.68(1), 
b=27.77(1 ), c:20.48(1 ), P=101.88(1 ) 0 , V=14,899i3. 
The ristocetin A iodide salt was soluble in water, 
dimethylformamide, dmso, methanol, ethanol, 80% acetone(aq)• 90% i-
propanol ( aq), 75% n-butanol in methanol, 40% ethyl acetate in methanol, 40% 
chloroform in methanol,30% carbon tetrachloride in methanol and was 
insoluble in diethyl ether. The results of crystallisation studies are 
presented in table 8.5. 
Table 8.5 Ristocetin A Iodide Salt Crystallisation Experiments 
Sample Solvent Precipitant Result(days) 
water 75%acetone neg(60) 
water 85%acetone neg(60) 
water 95%acetone amres(25) 
water 95%i-propanol neg(60) 
water n-BuOH/MeOH ( 4: ·1) amres(25) 
water /MPD (2: 1) MPD pptn(25) 
MeOH n-BuOH amres(6) 
MeOH ethanol pptn(6) 
MeOH acetone pptn(6) 
DMF diethyl ether amres(6) 
water ethanol neg(11) 
water i-propanol neg ( 11 ) 
water n-BuOH pptn(6) 
water chloroform pptn(6) 
Abbreviations: amres=amorphous residue, neg=no residue, 
pptn=precipitation, MPD=2~methyl-2,4-pentandiol 
n-BuOH=n-butanol, DMF=dimethylformamide, MeOH=methanol. 
All experiments were performed using 5mg ristocetin A 
iodide salt at 20°c with vapour diffusion of the precipitant. 
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Crystallisation by 'salting out' was performed as follows. Glass 
tubing (6cm long x 0,35cm i.d.) was sealed at one end with restricted-pore 
dialysis tubing (prepared by soaking Visking dialysis tubing in acetic 
anhydride/pyridine, 1:1, for 10 minutes), filled with aqueous ristocetin A 
solution (10%) and the other end sealed with a stopper. The tube was then 
immersed in a saturated salt solution (either ammonium sulphate or 
potassium dihydrogen phosphate). Both of the salts used produced clusters 
of very fine needle-like crystals but they were not suitable for x-ray 
analysis. 
8.2.5 RISTOCETIN- \.V -AGLYCONE 
Crystal studies were also performed on the w -aglycone derivative 
of ristocetin A which was soluble in water, methanol and ethanol, sparingly 
soluble in i-propanol and insoluble in acetone, diethyl ether, n-hexane, 
chloroform and methylene chloride. The results are presented in table 8.6. 
Table 8. 6 Ristocetin \.V -Aglycone Crystallisation Experiments 
Sample Sol vent Precipitant Result(days) 
water acetone pptn(5) 
water CH 2c1 2 /Me0H(1:1) pptn(5) 
water CHC1 3 /Me OH ( 1: 1) pptn(5) 
MeOH diethyl ether pptn(5) 
MeOH Et 20/Me0H(3:1) pptn(5) 
MeOH Et 20/Me0H(1:1) pptn(5) 
MeOH acetone/Me0H(1:1) neg(5) 
Abbreviations: pptn=precipitation, neg=no residue, 
Et 20=diethyl ether, MeOH=methanol. 
All experiments used 5mg ristocetin \.lJ - aglycone at 20°c 
with layering of the precipitant . 
The vapour diffusion experiment was modified in order to reduce the 
rate at which the precipitant condensed on the su'rface of the sample. The 
inner sample vial was sealed with a plastic cap which had a small hole 
pierced in it, thus limiting the rate of diffusion of the volatile solvent 
into the small vial. The results are presented in table 8. 7. 
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Table 8. 7 Ristocetin \IJ-Aglycone Crystallisation Experiments - 2 
Sample Sol vent Precipitant Result(days) 
methanol diethyl ether pptn(7) 
methanol chloroform pptn(7) 
methanol acetone pptn(7) 
methanol pet. ether * pptn(25) 
Abbreviations: pptn=precipitation, pet. ether=petroleum ether 
(boiling range 60°-8o 0 c). 
All experiments used 5mg antibiotic and vapour diffusion at 20°c. 
8.2.6 RISTOCETIN A/PEP'fIDE 
Experiments were also performed with ristocetin A and Ac-D-ala-D-
ala or Ac2-L-lys-D-ala-D-ala in solution together in order that crystals 
of the complex formed between them could be obtained. The results are 
presented in table 8.8. 
Table 8.8 Ristocetin A/Peptide Crystallisation Experiments 
Peptide 
dipep 
dipep 
dipep 
dipep 
dipep 
tripep 
Sample Solvent 
water 
water 
water 
water/MPD(1:1) 
water 
water 
Precipitant 
80%ethanol 
75%acetone 
90%methanol 
MPD 
75%acetone 
75%acetone 
Result(days) 
cryst(115) 
cryst(115) 
amres(115) 
pptn(115) 
cryst(7) 
cryst(7) 
Abbreviations: dipep=Ac-D-ala-D-ala, tripep=Ac2-L-lys-D-ala-D-ala, 
cryst=crystals, pptn=precipitation, amres=amorphous residue, 
MPD:2-methyl-2,4-pentandiol. 
All experiments used 10. 3mg antibiotic and either 1. 0mg dipeptide 
or 1.8mg tripeptide and vapour diffusion at 20°c. 
The crystals obtained from ristocetin A/tripeptide were not stable 
upon storage and decomposed within 2-3 days of being for.med. On the other 
hand, the crystals of ristocetin A/dipeptide (from water/75%acetone) were 
of high quality. Preliminary x-ray analysis of the latter complex has 
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shown the crystals to be cubic with 24 trimer units per unit cell. The cell 
volume was correspondingly large (--140,000A3). 
8.3 NMR EXPERIMENTS 
All nmr experiments were performed with 0.4-0.6ml samples in 5mm 
tubes. Three machines were used for the studies (exclusively proton) 
described in this dissertation. 
A Varian XL-100-15 (100MHz) machine was operated in the Fourier 
transform mode with a spectral width of 1000Hz ( 10.0ppm), a 90° pulse width 
of 0.07 seconds and 8192 data points (producing an acquisition time of 4 
seconds). Most of the 100MHz experiments were used for analysis only and 
with sufficient sample available that few transients (typically 16 or 
less) were necessary in order to obtain acceptable signal to noise in the 
spectrum. 
The conformational and mode of action studies were performed at 
higher field which resulted in spectral simplification. A Bruker WH-270 
(270MHz) with associated Nicolet software was operated in the Fourier 
transform mode with quadrature detection and phase alternation. A spectral 
width of 3000Hz (11.1ppm) was used, except when peptide was present in the 
binding .studies on vancomycin in which case 3500Hz ( 13.0ppm) was used. A 
pulse width of around 0.008 seconds was used in conjunction with 8192 data 
points and an acquisition time of 1.37 or 1.17 seconds ( for 3000Hz or 
3500Hz respectively). Finall~ a Bruker WH-400 (400MHz) with associated 
Bruker software -was operated in the Fourier transform mode with quadrature 
detection and phase alternation . Sensitivity enhancement was usually 
employed to reduce the effect of noise on the sp~ctrum. A spectral width of 
4000Hz (10.0ppm) was used, except for the vancomycin binding studies in the 
presence of peptide when 5200Hz (13.0ppm) was used. A 90° pulse of around 
0.008 seconds was used in addition to 8192 data points and an acquisition 
time of 1.02 or O. 79 seconds ( for 4000Hz or 5200Hz respectively). The 
400MHz reference spectra ( not the spectra obtained from double 
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irradiation) displayed in this thesis were enhanced by multiplication of 
the free induction decay by a Gaussian function, typically using a line 
broadening constant of -2 or -3 and a Gaussian factor ( actually the 
fraction of the FID containing useful information) of 0.3-0.35. A non-
Gaussian sensitivity enhancement was usually employed with all other 
spectra. This distinction between the enhancement methods arose because in 
practice the Gaussian function, although generally considered superior for 
sensitivity enhancement in most applications compared to the usual 
negative exponential function, was very time consuming to operate, 
typically taking 3-4 minutes for the data manipulation of 8192 data points 
compared to the 3-5 seconds for the simpler alternative. Obviously as the 
software improves this situation may change. 
Difference spectra were obtained by the simultaneous accumulation 
of a reference spectrum, ir1 which part of the spectrum void of any 
resonances was irradiated, and a series of spectra (typically up to 20) in 
which one resonance was irradiated in each. The standard Bruker 
microprograms were used throughout. Transients were accumulated up to a 
maximum of 2000 (usually less than 400) in multiples of 8 or 16. Typical 
decoupler power settings used were 5-9L for spin-decoupling experiments 
and -15-19L for nOe experiments. The following amounts of compound were 
used for the nmr studies. Triostin A ( 1 µmole, 1mg), aglucovancomycin 
( 10µmoles, 11.5mg), vancomycin ( 10µmoles, 15.0mg) and the corresponding 
multiples of peptide, Ac-D-ala-D-ala ( 1 Oµmoles, 2.0mg) and Ac2-L-lys-D-
ala-D-ala ( 10µmoles, 3.8mg). 
97 
9, REFERENCES 
1. M.H.McCormick, W.M.Stark, G.F.Pittenger, R.C.Pittenger and G.M.McGuire, 
Antibiotics Annual, 1955-1956, 606, 
2. M.G.Brazhnikov a, N.N.Lomakina, M.F.Lavrov a, I. V. Tolstykh, M.S. Yurina and 
L.M.Klyueva, Antibiotiki, 1963, 8, 392. 
3. M.P.Kunstmann, L.A.Mitscher, J.N.Porter, A.J.Shay and M.A.Darken, 
Antimicrobial Agents Annual, 1968, 242. 
4, V.A.Shorin, S.D.Yudnitsev and I.A.Kunrat, Antibiotiki, 1957, 5, 44. 
5. K.H.Michel and M.DeBono, Abstracts, 17th Interscience Conference, 
Antimicrob. Ag. Chemother., New York, 1977. 
6. M.R.Bardone, G.Tuan and C.Coronelli, Abstracts, 11th International 
Symposium on Chemistry of Natural Products, Golden Sands, Bulgaria. 
7. R.L.Hamill, W.M.Stark and D.C.DeLond, US Patent 4115552, 1978. 
8. A.P.Raun, US Patent 3816618, 1974. 
9. D.W.Ziegler, R.N.Wolfe and J.M.McGuire, Antibiotics Annual, 1956-1957, 
612. 
10. F. Tedesco, R.Markham, M.Gurwith, D.Christie and J.G.Bartlett, Lancet, 
1978, 226, 
11. M.R.B.Keithley, D.W.Burdon, Y.Arabi, J.Alexander-Williams, H.Thompson, 
D. Youngs, M.Johnson, S.Bentley, R.H.George and G.A.G.Mogg, Brit. Med. J., 
1978, 1667. 
12. W.E.Grundy, Antibiotics Annual, 1956-1957, 687. 
13. J . E.Philip , J.R.Schenck and M. P.Hargie, Antibiotics Annual, 1956-1957, 
699. 
98 
14. D.H.Williams, V.Rajananda and J.R.Kalman, J. Chem~ Soc., Perkin Trans. 1, 
1979, 787. 
15. H.A.Lechevalier and M.P.Lechevalier, Annual Review Microbiology, 1967, 
21, 71. 
16. J.E.Philip, J.R.Schenck, M.P.Hargie, J.C.Holper and W.E.Grundy, 
Antimicrob. Ag. Chemother., New York, 1960, 10. 
17. B.S.Coller, W.B.Lundberg and H.R.Gralnick, Thromb. Diath. Haemorrh., 
1975, 34, 83. 
18. M.A.Howard, R.A.Hutton and R.M.Hardisty, Brit. Med. J., 1973, 586. 
19. E.F.Mammen, Semin. Thromb. Hemostasis., 1971, 2, 61. 
20. M.A.Howard and B.G.Firkin, Thromb. Diath. Haemorrh., 1971, 26, 362. 
21. S.S.Kuwahara and W. T.Chambers, Experientia, 1978, 34, 532. 
22. J.Shoji and K.Katagiri, J. Antibiotics, Ser. A (Tokyo), 1961, 14,335. 
23. W.Keller-Schierlein, M.L.Mihailovic and V.Prelog, Helv. Chim. Acta, 
1959, 42, 305. 
24. W. Y.Chen, M.L.Hsu and R.K.Olsen, J. Org. Chem., 1975, 40, 3110. 
25. T.L.Ciardelli and R.K.Olsen, J. Am. Chem. Soc., 1977, 99, 2806. 
26. M.A. Viswamitra, O.Kennard, W.B. T.Cruse, E.Egert, G.M.Sheldrick, P.G.Jones, 
M.J.Waring, L.P.G.Wakelin and R.K.Olsen, Nature, 1981, 289, 817. 
27. J.S.Lee and M.J.Waring, Biochem J., 1978, 173, 115. 
28. M.J.Waring, in 'Antibiotics', Vol. 5, Pt. 2, ed. F.E.Hahn, Springer, 
Heidelberg, 1979, p.173. 
29. F.J.Marshall, J. Med. Chem., 1965, 8, 18. 
30. C.R.Johnson, Ph.D. thesis, University of Illinois, 1962. 
99 
31. P.J.Roberts, a.Kennard, K.Smith and D.H.Williams, J. Chem. Soc., Chem. 
Commun., 1973, 772. 
32. D.H.Williams and J.R.Kalman, Tetrahedron Lett., 1976, 4829. 
33. W.D.Weringa, D.H.Williams, J.Feeney, J.P.Brown and R.W.King, J. Chem. 
Soc., Perkin Trans. 1, 1972, 443. 
34. A.W.Johnson, R.M.Smith and R.D.Guthrie, J. Chem. Soc., Perkin Trans. 1, 
1972, 2153. 
35. K.A.Smith, D.H.Williams and G.A.Smith, J. Chem. Soc., Perkin Trans. 1, 
1974, 2369. 
36. G.A.Smith, K.A.Smith and D.H.Williams, J. Chem. Soc., Perkin Trans. 1, 
1975, 2108. 
37. D.H.Williams and J.R.Kalman, J. Am. Chem. Soc., 1977, 99, 2768. 
38. G.M.Sheldrick, P.G.Jones, a.Kennard, D.H.Williams and G.A.Smith, Nature, 
1978, 271, 223. 
39. M.G.Brazhnikova, N.N.Lomakina, F.Sztaricskai, M.M.Puskas, S.Makleit and 
R.Bognar, Kem. Kozlem., 1967, 27, 143. 
40. N.N.Lomakina, L.I.Muravyeva and M.Puskas, Antibiotiki, 1968, 13, 867. 
41. F.Sztaricskai, R.Bognar and M.M.Puskas, Acta chim. Acad. Sci. Hung., 
1975, 84, 75. 
42. M.P.Williamson and D.H.Williams, Tetrahedron Lett., 1980, 4187. 
43. F.Sztaricskai, A.Neszmelyi and R.Bognar, Tetrahedron Lett., 1980, 2983. 
44. F.Sztaricskai, I.Pelyvas and R.Bognar, Tetrahedron Lett., 1975, 1111. 
45. N.N.Lomakina, R.Bognar, M.G.Bra zhni kov a, F.Sztaricskai and 
L.I.Muravyeva, 7th International Symposium on the · Chemistry of 
Natural Products, Riga, 1970. 
100 
46. J.R.Fehlner, R.E.J.Hutchinson, D.S.Tarbell and J.R. Schenck, Proc. Nat. 
Acad. Sci. USA, 1972, 69, 2420. 
47. T.M.Harris, J.R.Fehlner, A.B.Raabe and D.S.Tarbell, Tetrahedron Lett., 
1975, 2655. 
48. C.M.Harris, J.J.Kibby, J.R.Fehlner, A.B.Raabe, T.A.Barber and T.M.Harris, 
J. Am. Chem. Soc., 1979, 101, 437. 
49. V.Rajananda, A.F.Norris and D.H.Williams, J. Chem. Soc. Pakistan, 1979, 
1, 29. 
50. D.H.Williams, V.Rajananda, G.Bojesen and M.P.Williamson, J. Chem. Soc., 
Chem. Commun., 1979, 906. 
51. J.R.Kalman and D.H.Williams, J. Am. Chem. Soc., 1980, 102, 897. 
52. H.Otsuka and J.Shoji, Tetrahedron, 1967, 23, 1535. 
53. T.J.Blake, J.R.Kalman and D.H.Williams, Tetrahedron Lett., 1977, 2621. 
54. J.R.Kalman, T.J.Blake, D.H.Williams, J.Feeney and G.C.K.Roberts, J. Chem. 
Soc, Perkin Trans. 1, 1979, 1313. 
55. H.T.Cheung, J.Feeney, G.C.K.Roberts, D.H.Williams, G.Ughetto and 
M.J.Waring, J. Am. Chem. Soc., 1978, 100, 46. 
56. E.Cundliffe, E.F.Gale, P.E.Reynolds, M.H.Richard and M.J.Waring, 'The 
Molecular Basis of Antibiotic Action', Wiley, 1972. 
57. C.H.Wallas and J.L.Strominger, J. Biol. Chem., 1963, 238, 2264. 
58. P.E.Reynold s, Biochim. Bio phys. Act a, 1961, 52, 40 3. 
59. D.C.Jordan , Biochem. Biophys. Res. Commun., 1961, 6, 167. 
60. H.R.Perkins, Biochem. J., 1969, 111, 195. 
61. M.Nieto and H.R.Perkins, Biochem. J., 1971, 123, 773. 
101 
62. M.Nieto and H.R.Perkins, Biochem. J., 1971, 123, 789. 
63. M.Nieto and H.R.Perkins, Biochem. J., 1971, 124, 845. 
64. J.P.Brown, J.Feeney and A.S.V.Burgen, Mol. Pharmacology, 1975, 11,119. 
65. J.P.Brown, L. Terenius, J.Feeney and A.S. V.Burgen, Mol. Pharmacology, 
1975, 11, 126. · 
66. O.Convert, A.Bongini and J.Feeney, J. Chem. Soc., Perkin Trans. 2, 1980, 
1262. 
67. J.R.Kalman and D.H.Williams, J. Am. Chem. Soc., 1980, 102, 906. 
68. E.Schnabel, Liebigs Ann. Chem., 1967, 702, 188. 
69. M.Itoh, D.Hagiwara and T.Kamiya, Tetrahedron Lett., 1975, 4393. 
70. B.F.Erlanger and R.M.Hall, J. Am. Chem. Soc., 1954, 76, 5781. 
71. L.Zervas, M.Winitz and J.P.Greenstein, J. Org . Chem., 1957, 22, 1515. 
72. G.W.Anderson, J.E.Zimmerman and F.M.Callahan, J. Am. Chem. Soc., 1964, 86, 
1839. 
73. D.H.Williams and D.W.Butcher, J. Am. Chem. Soc., 1981, in press. 
74. D.H.Williams, personal communication. 
75. W.B. T.Cruse, personal communication . 
76. M.P.Williamson and D.H.Williams, J. Chem. Soc., Chem. Commun., 1981, 165. 
77. R.C.Pandey, R.Misra and K.L.Rinehart, J. Chromatog., 1979, 170, 498. 
78. P.G.Jones, Chem. in Brit., 1981, 17, 222. 
102 
APPENDIX 1 
SELECTED BIBLIOGRAPHY 
( 1) BACTERIAL CELL WALL 
(a) P.M.Meadow, in 'Companion to Biochemistry - Selected Topics for 
Further Study', eds. A~ T.Bull, J.R.Lagnado, J.O.Thomas and . 
K.F. Tipton, Longman, 1974, ch.10. 
( b) J -M.Ghuysen and G.D.Shockman, in 'Bacterial Membranes and 
Walls', ed. L.Leive, Marcel Dekker Inc., New York, 1973, ch.2. 
(c) P.M.Blumberg and J.L.Strominger, Bacteriol. Rev., 1974, 38, 291. 
(2) MODES OF ACTION OF ANTIBIOTICS 
( a) T .J.Franklin and G.A.Snow, 'Biochemistry of Antimicrobial 
Action', 3rd Edn., Chapman and Hall, 1981. 
(b) E.F.Gale, E.Cundliffe, P.E.Reynolds, M.H.Richmond and M.J.Waring, 
'The Molecular Basis of Antibiotic Action', Wiley, 1972. 
(3) THE VANCOMYCIN GROUP OF ANTIBIOTICS 
D.H.Willi9ms, V.Rajananda, M.P.Williamson and G.Bojesen, in 'Topics in 
Antibiotic Chemistry', Vol.5, ed. P.Sammes, Ellis Horwood, 1980, p119. 
(4) THE QUINOXALINE ANTIBIOTICS 
M.J.Waring, in 'Antibiotics', Vol.5, Pt .2, ed. F.E.Hahn, Springer , 
Heidelberg, 1979, p 173. 
103 
( 5) NHR SPECTROSCOPY 
(a) H.Gunther, 'NMR Spectroscopy', Wiley, 1980. 
( b) D.H.Williams and I.Fleming, 'Spectroscopic Methods in Organic 
Chemistry', 2nd Edn., McGraw-Hill, 1973, ch.3. 
(c) T.C.Farrar and E.C.Becker, 'Pulse and Fourier Transform NMR -
Introduction to Theory and Methods', Academic Press, 1971 . 
(d) D.Shaw, 'Fourier Transform NMR Spectroscopy', Elsevier, 1976. 
(e) J.W.Cooper, in 'Transform Techniques in Chemistry', ed. 
P.R.Griffiths, Plenum, 1978, ch.4. 
( f) T .C.Farrar, ibid., ch.8. 
104 
